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Tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an 
inflammatory disorder which affects up to 54% of TB-HIV co-infected patients. Its 
pathogenesis remains unclear, and although treatment with the corticosteroid prednisone 
has shown some benefits, there is no specific treatment currently available for TB-IRIS. N-3 
polyunsaturated fatty acids (PUFA) have safely and successfully been used in the treatment 
of other inflammatory diseases, and we hypothesized that they will have beneficial anti-
inflammatory effects on TB-IRIS patient-derived immune cells.  
 
To investigate this hypothesis, we used mass spectrometry (MS)-based proteomic methods 
to probe the secretome of peripheral blood mononuclear cells (PBMCs) re-stimulated ex vivo 
with Mycobacterium tuberculosis (Mtb) whole cell lysate (WCL), and treated with n-3 PUFA. 
Optimization experiments were performed on cells obtained from eight healthy donors to 
assess the secretome changes induced by re-stimulation with Mtb WCL and treatment with 
n-3 PUFA. In addition, experiments were repeated using PBMCs obtained from five non-IRIS 
and five TB-IRIS patients. The secretome was prepared via chloroform/methanol precipitation 
and overnight Trypsin digestion, and investigated via MS-based shotgun proteomics. 
MaxQuant was used for protein identification and Perseus for statistical analysis.  
 
Stimulation with Mtb WCL shifted the secretome of healthy PBMCs towards an inflammatory 
state, and this was altered by treatment with EPA/DHA via changes in the regulation of several 
proteins.  Preliminary results from TB-IRIS patient-derived PBMCs show the same trend. These 
promising early results suggest the potential benefits of n-3 PUFA dietary supplementation 
for patients with TB-IRIS, and warrant further studies with increased sample size to confirm 
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1.1.1 Significance of disease 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb), 
and is especially common in low-resource settings. TB is the leading cause of death by infectious 
disease world-wide with 1.6 million deaths and an estimated 10.4 million new infections in 2016.1 It is 
distributed primarily to low-income countries: the top six affected are India, Indonesia, China, Nigeria, 
Pakistan, and South Africa. Africa carries a large part of the burden with 25% of the total number of 
TB cases in this region, and South Africa has the highest incidence rate in the world with 781 cases per 
100,000 people2 (Figure 1).  It is therefore a significant public health concern. 
Figure 1. Estimated incidence rates for TB in 2016 





1.1.2 Mycobacterium tuberculosis (Mtb) 
Mtb has been evolving alongside its human host for thousands of years and is a highly adapted 
pathogen. A recent genetic study indicates that Mtb emerged roughly 70,000 years ago and followed 
humans on their “Out of Africa” migration.3 The bacterium is a small intracellular bacillus with a 
doubling time of 12-24 hours. A defining feature of Mtb is its complex cell wall structure, which renders 
it highly impermeable to pharmacological compounds and thereby contributes to its virulence and 
persistence. The high-lipid content of this cell wall also makes it impermeable to most dyes, meaning 
Mtb is classified as an acid-fast rather than gram-positive or -negative bacterium (once stained, it 
cannot be decolourised by acid detergents). 
 
The cell wall (Figure 2) is made up of three covalently linked layers: peptidoglycans (grey) and 
arabinogalactans (blue) form the inner layers, and mycolic acids (green) the outer layer4. The 
extremely low fluidity of the outer, hydrophobic mycomembrane results from covalent bonds 
between the large hydroxylated branched-chain mycolic acids. Intercalated between these are free 
lipids specific to mycobacteria, such as phenolic glycolipids, phthiocerol dimycocerosates, cord factor 
or dimycolyltrehalose, sulpholipids, and phosphatidylinositol mannosides. The outer capsule contains 
the polysaccharides glucan and arabinomannan. 
 
Protein secretion systems are essential to mycobacterial survival and virulence, and five different type 
VII secretion systems were identified in Mtb (ESX1 – 5). ESX1 secretes the antigens ESAT-6 and CFP-
10, and allows Mtb to persist in the macrophage. ESX1 is crucial for virulence and loss of this system 
contributes to the lack of pathogenicity of  Mycobacterium bovis, which is used in the Bacille Calmette-




Figure 2. Schematic diagram of the cell wall structure of Mycobacterium tuberculosis 
This representation shows a cross section of the cell envelope of Mtb including the three covalently 
linked layers: the peptidoglycan and arabinogalactan layer (grey and blue), the mycolic acid layer 
(green), as well as the outer polysaccharide layer. (Figure sourced from Abdallah et al., 2007)4 
 
1.1.3 Pathogenesis of tuberculosis 
Immune response 
TB is highly infectious and communicable by aerosolized droplets. In active pulmonary TB, patients 
will cough and produce droplets containing exhaled bacilli that can enter the body by inhalation. A 
study conducted on rabbits5 showed that smaller droplets are more likely to result in infection, and 
these findings were later confirmed in human studies.6 Small droplets containing one to three bacilli 
are able to reach the lung alveoli whereas larger droplets would get stuck in the upper airways, where 
the bacteria could be eliminated by commensal-primed mucosal barrier immunity. Mucosa-lined 
airways contain microbicidal macrophages that are activated by commensal bacteria via toll-like 
receptor (TLR) pathways, and are continually recruited to remove potential pathogens from the 
trachea and nasal passages. By reaching deeper into the lower lung which contains few commensal 




The cellular components of the innate immune system, the alveolar resident macrophages, are the 
first to encounter Mtb. Phagocytosis is facilitated via opsonic and non-opsonic recognition through 
various receptors, including scavenger receptors, mannose receptors, and complement receptors. 
Phagocytosed bacteria can then be eliminated by production of reactive oxygen/nitrogen species 
(ROS/RNS), acidification of the phagosome, and phagosome/lysosome fusion. However, macrophages 
often fail to destroy the engulfed bacteria in this way due to Mtb’s ability to survive inside phagocytic 
cells. To achieve this, Mtb arrests maturation of the phagosome/lysosome complex,8 restricts 
acidification, and prevents fusion with the lysosome, as was first shown by Armstrong and Hart.9 
Furthermore, Mtb produces two enzymes that allow it to resist oxidative killing by toxic peroxide 
species: mycobacterial catalase-peroxidase (KatG), and alkyl hydroperoxide reductase (AhpC).10 Mtb 
is also able to stop infected macrophages from undergoing apoptosis, causing them to rather go into 
a necrotic state. Necrosis is a type of cell death that involves cell lysis, and which the pathogen can 
use to exit the macrophage, spread, and infect new macrophages.11 Lastly, the bacterium causes 
changes in cytokine production and thereby affects the shape of the immune response. This allows it 
to avoid detection, and to induce inflammation that will result in liquefaction of the granuloma, thus 
producing an infectious cough that will lead to transmission.12 
 
Bacilli that have not been eliminated by macrophages will replicate and exit the infected cell after 
phagocytosis. Bacteria are then recognised and taken up by professional antigen-presenting cells 
(APC), such as dendritic cells (DC), through C-type lectin receptor (CLR-) and TLR-mediated recognition. 
After processing the engulfed pathogen, DCs present Mtb antigens to naïve T cells in lymph nodes. 
CD4+ T cells are then activated by extracellular antigens presented on major histocompatibility 
complex-II (MHC-II), and CD8+ T cells are activated by intracellular antigens presented on MHC-I. After 
activation, T cells undergo clonal expansion and migrate to the site of infection. Interferon-gamma 
(IFN-γ) is then released by T cells to activate macrophages and induce production of nitric oxide 
synthase (NOS) as an intracellular killing mechanism. CD4+ T cells also release tumor necrosis factor-
alpha (TNFα), thereby further activating other monocytes, macrophages, and DCs, while CD8+ T cells 
eliminate Mtb directly by releasing the cytolytic toxins perforin and granulysin (both form pores in 
target cell membrane) and granzymes (induce apoptosis via Fas-Fas-L pathway).12  
 
The type 1 CD4+ helper T cell (Th1) response is geared toward the elimination of intracellular 
pathogens, and is therefore very important in fighting off Mtb infection. DCs release interleukin 12 (IL-
12), which shapes the immune system towards a Th1-dominant response. The importance of IFN-γ 
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release by Th1 CD4+ T cells in TB was shown in patients with IFN-y receptor 1 gene deletions, causing 
depletion of IFN-γ.13 Type 17 helper T cells (Th17) are also important in controlling TB, as release of IL-
17 by Th17 cells facilitates the recruitment and activation of neutrophils and Th1 CD4+ T cells.12 
However, recent studies have shown that excessive Th17 stimulation leads to tissue damage by  
inflammation due to increased migration of neutrophils and inflammatory monocytes to the site of 
infection.14 Counter-balancing the Th1 response is the Th2 response, which inhibits the former by 
production of IL-4, IL-5, and IL-10. Similarly, regulatory T cells (Treg) have a suppressive effect on Th1 
and Th17, also mediated by their ability to release IL-10 and transforming growth factor-beta (TGF-β). 
In active disease, Treg cells accumulate at the site of infection and are associated with poor 
containment. In addition to these, “unconventional” T cells, such as γδ T cells, are thought to be 
involved in the control of TB by recognising non-peptide components of Mtb and initiating 
inflammation responses and cytotoxicity.15 Mucosal-invariant T cells (MAIT) are another population of 
specialized T cells which can identify bacterial metabolites via the major histocompatibility complex-
like molecule MR1, and play an important role in the detection of intracellular Mtb infection.16 
 
Granuloma formation 
In the great majority of people infected with TB, the bacteria is effectively contained in granulomas, 
the formation of which is the hallmark in the progression of TB disease (Figure 3). Infected 
macrophages release IFN-γ, TNF-α, and other inflammatory cytokines to recruit immune cells 
(neutrophils, natural killer T cells (NKT), CD4+, and CD8+ T cells) from nearby blood vessels to the site 
of infection. Amplification of recruitment signals is mediated by the production of other inflammatory 
cytokines by each of these immune cells. The granuloma structure then begins to form around a 
central core of infected macrophages, surrounded by foamy macrophages (macrophages loaded with 
lipid droplets). Other mononuclear cells, as well as giant cells (large multinucleated cells, which form 
as a result of several monocytes/macrophages fusing together), continue to build on to the 
granuloma. A fibrous cuff of collagen surrounds and delineates the structure. During granuloma 
maturation, the fibrous sheath increases while the blood vessels which perfuse the structure 
disappear. If a change in the immune status of the host occurs, such as malnutrition or HIV infection, 
the granuloma may become caseous and decay into a mass of cellular debris, leading to the rupture 






Figure 3. Schematic representation of the formation and structure of the granuloma 
Phagocytosed bacilli replicate inside macrophages and promote the recruitment of immune cells to 
the site of infection. The granuloma forms around a central core of infected macrophages, foamy 
macrophages, giant cells, and other mononuclear cells. A fibrous and collagen cuff forms around the 
granuloma in the mature stage, and the structure breaks open during caseation, releasing bacilli into 
the airways. (Figure sourced from Rayasam et al., 2015)18 
 
1.1.4 Diagnosis 
Rapid and accurate diagnosis of TB is essential for the effective treatment and control of the disease. 
Although several detection methods for Mtb are available, early detection is still hampered by low-
resource settings at point-of-care (POC) as well as a high number of false negative test outcomes due 
to the low sensitivity of many tests, especially in immuno-compromised patients. In addition to this, 
no test is able to give a differential diagnosis for active TB and latent TB (LTBI). As only 5-15% of people 





Microbiological culture and microscopy 
Detection of the causative agent Mtb through microscopy is one of the direct diagnostic methods. The 
'gold standard' for TB diagnosis remains the culture of bacilli from clinical samples and subsequent 
detection through microscopy. However, growth of Mtb is slow, taking two or more weeks on average 
before detection, and requires trained staff as well as a well-equipped laboratory.19 
 
Sputum smear microscopy, developed more than 100 years ago, is often the preferred method20 as it 
is cheaper and requires minimal biosafety standards, although the presence of Mtb bacilli is only 
identified in 44% of new cases, and 15-20% of children sputum samples.21 Sputum smear microscopy 
lacks sensitivity in children and HIV-infected patients, who may have very low bacillary loads, and 
cannot distinguish between Mtb and other non-tuberculous mycobacteria.19 
 
Tuberculin skin test (TST) 
Today the tuberculin skin test (TST) remains the most wide-spread TB diagnostic test, even with recent 
advances in other more sensitive molecular tests.20 The TST uses the immune response to TB antigens 
as a proxy for diagnosis of the disease. A standard preparation of purified protein derivative (PPD) is 
injected intradermally, and the patient is re-examined 48 to 72 hours later. The resulting skin reaction 
is exaggerated in persons who have previously mounted an inflammatory response to TB antigens.  If 
the diameter of the reaction area is greater than or equal to 10 mm, the reaction is considered 
positive. However, false positives occur if the individual has been vaccinated with the BCG vaccine, 
and false negatives are common in immunocompromised patients, such as HIV- infected individuals, 
who do not mount a normal immune response.21 
 
Interferon-gamma release assays (IGRAs) 
Interferon-gamma release assays (IGRAs) are ex vivo blood tests that measure the presence of 
mycobacteria-specific T cell responses to the antigens ESAT-6 (6kDa early secreted antigenic target), 
CFP-10 (culture filtrate antigen), and TB7.7, using ELISA (QFT-G test) or ELISPOT (T-SPOT.TB test).20 
However, IGRAs may result in false negatives in high TB/HIV-burden settings as they rely on the 
indirect measurement of the individual's immunological response, and the WHO has therefore advised 





Nucleic acid amplification tests (NAATs) 
Nucleic acid amplification tests (NAATs) use PCR to amplify and detect mycobacterial RNA or DNA 
from any clinical sample. However, they show poor sensitivity and specificity in smear-negative TB and 
the cost associated with these tests means they are not widely used. The most advanced NAAT is the 
Xpert MTB/RIF assay which can confirm the presence of Mtb and identify resistance mutations within 
two hours. Unfortunately, high costs and the sophisticated equipment required to perform these tests 




TB is treated with combination drug therapy in order to limit the risk of developing drug resistance. 
Each drug has a different mechanism and by combining these, chances of treatment success are 
increased. The recommended oral first-line drugs are isoniazid (H), rifampicin (R), ethambutol (E), and 
pyrazinamide (Z).23 The standard regimen for adults and children over 30 kg is 2HRZE (intensive phase 
consisting of two months’ treatment with H, R, Z, and E), followed by 4HR (continuation phase with H 
and R for four months). 
 
Table 1. First-line drugs for treatment of TB, single-letter abbreviations and mechanism of action 
Drug name Single-letter 
abbreviation 
Mechanism of action 
Isoniazid H Bactericidal/bacteriostatic; target InhA and inhibits synthesis of 
mycolic acids24 
Rifampicin R Bactericidal; inhibits bacterial DNA-dependent RNA 
polymerase25 
Ethambutol E Bacteriostatic; inhibits arabinosyl transferase 
Pyrazinamide Z Bactericidal; disrupts membrane energetics and inhibits 
membrane transport systems26 
 
According to the South African National Tuberculosis Management Guidelines,27 the patient’s 
infection status must be re-assessed one week before the end of the intensive phase (week 7) via 
sputum smear microscopy. If the result is negative, the patient progresses onto the continuation 
phase at the end of week 8, and is considered to respond well to treatment. If the sputum smear is 
still positive at week 7, the patient's compliance to treatment is assessed, and the intensive phase is 
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prolonged for one month. These patients are then checked again at week 11 and if the sputum smear 
remains positive, further testing is done to establish drug susceptibility and resistance. If drug-
resistant (DR) TB is confirmed, DR-TB treatment is initiated (see DR-TB treatmentDR-TB treatment). 
Finally, patients having progressed to the continuation phase are assessed at week 23 and treatment 
is stopped at the end of week 24 if results from sputum smear microscopy are negative. If still positive, 
line probe assays (LPA) or drug susceptibility testing (DST) are performed to check for resistance to Z 
and/or E. If patient’s infection is drug-susceptible, treatment is re-started from the beginning and the 
patient is counselled on the importance of compliance. 
 
DR-TB treatment 
According to the WHO TB country profile, there were 20,040 cases of DR-TB in South Africa in 2016.19 
There are several factors contributing to the emergence of these drug-resistant TB cases, including 
poor treatment adherence, as well as poor management of drug supply and access to health care and 
treatment in low-resource settings. DR-TB is classified as rifampicin-resistant only (RR-TB), multi-drug 
resistant (MDR-TB; resistant to at least both H and R), extensively drug-resistant (XDR-TB; resistant to 
at least H, R, one of the fluoroquinolones and one of the second-line injectables). 
 
According to the WHO treatment guidelines,23 all MDR-TB patients should receive a four-drug regimen 
with one drug from Group 2 (kanamycin and amikacin are first choice), one from Group 3, with 
ethionamide (Group 4) often added due to its low cost. Group 5 drugs are only recommended in cases 
where it is impossible to design an adequate regimen using drugs from groups 2 to 4, and in cases of 
XDR-TB. Some of the second-line drugs used to treat DR-TB are listed in Table 2 below (non-exhaustive 
list). MDR-TB patients are monitored monthly for sputum conversion, and treatment is continued for 
at least four months after conversion. Treatment may be as long as 24 months in chronic cases with 












1.2 HIV and AIDS 
1.2.1 Significance of disease 
HIV is a global leading cause of morbidity and mortality with 36.7 million people infected in 2016, 1.8 
million new infections and 1 million deaths.28 Sub-Saharan Africa (SSA) is particularly affected by the 
epidemic, and carries 70% of the global HIV burden. South Africa alone has the highest number of HIV-
positive people in the world (estimated 7.1 million in 2016) and one of the highest rates of prevalence 
(estimated 18.9% in adults aged 15 to 49 years).29 The prevalence of HIV across the world is shown in 











Group Type Drug name 
Group 2 Second-line injectables Kanamycin 
Amikacin 
Streptomycin 
Group 3   Fluoroquinolones Levofloxacin 
Moxifloxacin 
Group 4   Oral bacteriostatic Ethionamide 







Figure 4. HIV prevalence amongst adults 15-49 years by WHO region in 2016 
(Figure sourced from the WHO, Global Health Observatory, 2017)30  
 
The global large-scale deployment of anti-retroviral therapy (ART) has been one of the most successful 
recent public health interventions, giving access to treatment for 3.4 million people in South Africa 
alone – more than any other country. This increase in treatment is largely responsible for the 26% 
decrease in AIDS-related mortality since 2010.31 
 
1.2.2 The virus 
The HI virus is part of the Lentivirus genus and Retroviridae family. Lentiviruses ('lenti' meaning 'slow' 
in Latin) have long incubation periods and cause long-term illness to their host. Two types of HI viruses 
have been characterized: HIV-1 shows higher virulence and infectivity and is responsible for most HIV 
infections globally, while HIV-2 is less genetically diverse and largely confined to West Africa.32 
 
Structure 
The HI virion consists of a spherical viral envelope containing a conical capsid, which houses several 
enzymes and two strands of positive ssRNA. The viral envelope is formed from the lipid bilayer of the 
host cell when the virus capsid buds off and is released. It includes the glycoproteins gp120 and gp41 













Figure 5. Diagrammatic representation of the structure of the HI virion 
(Figure sourced from Wikimedia Commons)33 
 
 
1.2.3 Life cycle 
Binding and entry 
HIV uses its surface glycoproteins gp120 and gp41 to bind and anchor itself to CD4 glycoproteins on 
the surface of host immune cells, such as helper T cells, monocytes, macrophages, and dendritic cells. 
C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4) are engaged in 
interaction and gp120 and gp41 undergo conformational changes to allow fusion of the host cell 
plasma membrane with the viral membrane.34 
 
Viral transcription and replication 
Shortly after entry into the target cell, the two ssRNA strands are released from the viral capsid by the 
enzyme reverse transcriptase (RT) and copied to complimentary DNA (cDNA). Viral RT also has 
ribonuclease activity to degrade RNA, as well as DNA-dependent DNA polymerase activity to create a 
sense DNA strand from the antisense cDNA. These two complimentary DNA strands are transported 
to the host cell nucleus and integrated into the host genome by the viral enzyme integrase. The 
integrated viral DNA may then lie dormant (latent infection phase) until certain cellular transcription 
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factors, such as NF-κB, are activated. These factors are normally present during activation of the 
immune system in response to infection, therefore the more the immune system tries to fight off 
infection, the more HIV is transcribed. 
 
Viral recombination, assembly, and budding 
Two copies of viral RNA are encapsulated in the virion thus allowing for recombination between the 
two different genomes during replication by RT. It is estimated that two to 20 recombination events 
occur per genome and per replicative cycle. The shuffling of polymorphisms between viruses increases 
viral genetic diversity and therefore pathogenesis and virulence, giving the virus a better chance at 
escaping the pressures exerted by its host.35 
 
1.2.4 Pathogenesis and disease 
Transmission and diagnosis 
Heterosexual transmission is responsible for approximately 85% of all HIV infections.36 Prevalence of 
HIV is correlated with other sexually transmitted diseases, as well as certain sexual practices, such as 
concomitant relationships, and alcohol and drug use. HIV diagnosis relies on the detection of 
antibodies or antigens specific to the virus from various patient samples including plasma, serum, 
whole blood, or saliva. However, serological tests are ineffective during primary infection (before the 
body has produced antibodies) and in infants younger than 18 months born to HIV-positive mothers, 
who might carry maternal HIV antibodies.36  
 
Disease progression 
The early stages of HIV infection are frequently asymptomatic, although viral replication takes place 
at a constant rate throughout infection. Viral replication leads to the gradual decimation of the CD4+ 
T cell population eventually leading to AIDS during the later stages. To monitor disease progression, 
viraemia is measured via quantification of viral RNA. CD4+ cell counts are also monitored using flow 
cytometry, and clinical symptoms such as opportunistic infections are indicators of immune 
deficiency. In the early stages, viral load is quickly reduced following HIV-specific CD8+ responses, but 
the chronic phase of the disease starts at the formation of latent viral reservoirs in resting HIV-infected 





ART leads to long-term viral suppression and reduced mortality and morbidity, but does not achieve 
full clearance of HIV from the system and treatment must be continued throughout the patient’s life. 
Due to the high rate of viral replication and potential for recombination and mutation, a three-drug 
combination regimen (highly active ART, HAART) is needed to limit drug resistance and improve 
effectiveness. The main classes of drugs used to treat HIV include viral non-nucleoside and 
nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs and NRTIs, respectively), and protease 
inhibitors (PIs). ART usually includes two NRTIs, in addition to an NNRTI or PI. UNAIDS guidelines 
stipulate that ART should be started ideally in all individuals living with HIV, and that it should be 
initiated in priority in patients with a CD4+ count below 350 cells/mm3, as well as in pregnant and 
breast-feeding women and children under the age of two regardless of CD4+ cell counts.37 
 
1.3 TB-IRIS 
1.3.1 HIV and TB 
HIV co-infection is present in approximately 60% of TB cases in South Africa.2 HIV and TB are synergistic 
pathogens and TB is a leading cause of death in HIV-infected patients. HIV reduces the frequency and 
function of CD4+ T-cells, thereby exacerbating the progression of existing TB, while the host immune 
response to TB, which includes the activation of mononuclear cells, also promotes replication of HIV 
and progression to AIDS.38 An estimated 25% of HIV-infected individuals are also infected with latent 
TB, and are 26 times more likely to progress to active TB than their HIV-negative counterparts.39 As 
previously stated, diagnosis of TB in HIV+ individuals is complicated by concurrent HIV infection and 
immune suppression. Sputum smear microscopy is more likely to be negative in such patients, with 
active TB successfully identified in 22-43% of cases only.40 In addition to this, the TST is also more likely 
to be negative, and disease is more frequently disseminated to extra-pulmonary sites thereby 
complicating diagnosis through standard methods. Anti-TB treatment and its timing must be 
considered carefully in HIV+ patients as the potential for drug-drug interactions is high, as is the 
development of TB-associated immune reconstitution inflammatory syndrome (IRIS).  
 
In a subset of HIV and TB co-infected patients, treatment is complicated by TB-IRIS, a disorder 
characterized by a post-ART worsening of existing TB after previous response to anti-TB therapy 
(paradoxical TB-IRIS) or the emergence of new or previously subclinical TB disease (unmasking TB-
IRIS). For the purposes of this project, only paradoxical TB-IRIS will be investigated. Although several 
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pathogens can cause IRIS, mycobacterial infections such as TB are responsible for approximately 40% 
of cases.41 The reported incidence of TB-mediated IRIS varies from 10 to 54%,42,43 with an estimated 
mortality rate of 3.2%,44 and it is especially prevalent in South Africa, where the rate of TB and HIV co-
infection is high and ART is readily available. 
 
1.3.2 Pathogenesis 
The dysregulated restoration of immune responses in ART-treated patients was first reported in 
199245 and the syndrome is well-known today. Although the immunopathogenesis of TB-IRIS is 
incompletely understood, it is thought to be multifactorial, and is believed to result from an 
inappropriately regulated host response to antigenic stimuli upon immune recovery.  
 
TB-IRIS was shown to be associated with increasing peripheral frequency of antigen-specific IFNγ+ 
Th1, as well as a 24% increase in T cell activation markers at IRIS onset.46 Bourgarit and colleagues 
additionally demonstrated an increase in the Th1 cytokines/chemokines IL-2, IL-12, IP10, and 
MIG/CXCL9, as well as other pro-inflammatory cytokines/chemokines (TNF-α, IL-6, IL-1β, IL-10, 
RANTES, and MCP-1). However, no Th2 cytokine peak occurred. Similarly, Vignesh and colleagues47 
found that TB-IRIS was associated with CD3+CD4- and CD4+ T cell responses against Mtb antigens, and 
presence of these cells at baseline may therefore suggest a predisposition to IRIS in certain patients. 
A dysregulated Th1 cell expansion has also been noted in association with TB-IRIS in other studies,48,49 
although expansion of the Mtb-specific Th1 population was also observed in patients who do not go 
on to develop TB-IRIS, calling into question the importance of this population expansion in the 
pathogenesis of TB-IRIS.48 
 
Although findings by Meintjes and colleagues48 suggest that the central role of Th1 in TB-IRIS 
pathogenesis be reconsidered, these responses are undoubtedly of crucial importance during the 
immune response to TB, and are likely involved in generating the TB-IRIS phenotype. Clinical studies 
investigating differential cytokine levels in TB-IRIS patient samples have been conducted,46,50,51  and 
several different cytokines (e.g., IL-6, IFNγ, TNFα, etc.) were found in these studies to be relatively 





1.3.3 Risk factors, diagnosis, and treatment 
Diagnosis of TB-IRIS is challenging due to the lack of reliable diagnostic markers, the variable 
presentations, and the need to exclude differential diagnoses, such as TB drug resistance.52 Risk 
factors for paradoxical TB-IRIS have been identified, including low CD4+ cell count at baseline,53 rapid 
CD4+ count recovery post-ART,53 disseminated TB, a short time interval between initiation of anti-TB 
therapy and ART,53,54 as well as potential genetic variations.55 
 
Given the temporal association between the initiation of ART treatment and the development of TB-
IRIS, delaying the start of ART may reduce the risk of TB-IRIS.54 However, even short delays in ART 
initiation in TB patients are associated with a high risk of mortality in severely immunocompromised 
patients (CD4 count <50). Recommendations regarding co-treatment with anti-TB drugs and ART state 
that ART should be initiated within 2 weeks of anti-TB treatment in patients with a CD4+ count <50 
cells/mm3, and may be delayed for up to 8 weeks if immunodeficiency is less severe.56 
 
A randomised placebo-controlled trial, conducted in a South African TB-IRIS cohort, has shown the use 
of prednisone, a broad-spectrum corticosteroid, to be effective in “reducing the need for 
hospitalisation and therapeutic procedures, and hastening improvements in symptoms, performance 
and quality of life”.57 The prescription of corticosteroids in HIV patients does carry several risks, 
including the development and progression of herpes zoster58 and Kaposi’s sarcoma.59 Additionally, 
re-emergence of TB-IRIS in a subset of patients after cessation of prednisone suggests that 
corticosteroids do not necessarily correct the pathogenic mechanisms underlying TB-IRIS. More 
specific prophylactic and therapeutic treatment options for TB-IRIS are therefore required. 
 
1.4 N-3 polyunsaturated fatty acids (PUFA) 
1.4.1 Mechanism of action 
N-3 polyunsaturated fatty acids (PUFA) are potent immune-modulatory agents that can inhibit certain 
aspects of inflammation, such as recruitment of leucocytes, cellular adhesion, production of 
eicosanoids (leukotrienes and prostaglandins) from n-6 arachidonic acid, cytokine release, and Th1 
activity.60 The most potent n-3 PUFA are the long-chain PUFA derived from marine oils in the diet, 
namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA, Figure 6). EPA, and to a certain 
extent DHA, is able to compete with n-6 arachidonic acid as an enzymatic substrate in the production 
of eicosanoids and thereby reduce inflammation.61 Furthermore, both EPA and DHA give rise to pro-
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resolving mediators such as resolvins, protectins, and maresins. N-3 PUFA are also able to modulate T 
cell-mediated processes specifically, such as altering lipid raft formation at the immunological synapse 
where T cells and APCs interact for antigen-initiated T cell signalling, and upregulating the Th2 cells 







Figure 6. Structures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)63 
 
Since humans do not have the enzymes necessary to inter-convert n-3 and n-6 PUFA, dietary 
differences in the ratio of the fatty acids are reflected at the physiological level. Arachidonic acid (AA) 
arises from the essential acid linoleic acid (LA), which is obtained from dietary sources such as 
safflower and sunflower oils. AA is an important part of the plasma membrane phospholipids and can 
produce potent pro-inflammatory eicosanoids, such as leukotrienes and prostaglandins, when acted 
on by cyclooxygenase (COX) and lipoxygenase (LOX). On the other hand, EPA and DHA are derived 
from α-linolenic acid (ALA), an essential fatty acid obtained from certain nuts/seeds (walnuts, chia, 
and linseed). When acted on by COX and LOX, these fatty acids give rise to the inflammatory-resolving 
mediators resolvins, protectins, and maresins. 64 The metabolism of n-3 and n-6 fatty acids is depicted 













Figure 7. Metabolism of n-3 and n-6 PUFA 
Arachidonic acid (AA) arises from the essential acid linoleic acid (LA), and produces pro-inflammatory 
eicosanoids, such as leukotrienes and prostaglandins (lipoxins are usually pro-resolving), when acted 
on by cyclooxygenase (COX) and lipoxygenase (LOX). Eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are derived from α-linolenic acid (ALA), and compete with AA for as 
enzymatic substrates to give rise to pro-resolving resolvins, protectins, and maresins. (Figure sourced 
from Hidaka et al., 2015)64 
 
1.4.2 Clinical use 
N-3 PUFA have an excellent tolerability and safety profile, and are thus attractive as potential 
therapeutic agents for a range of inflammatory and auto-immune diseases.65 Several clinical trials 
support the beneficial effects of dietary n-3 PUFA supplementation in chronic inflammatory diseases 
such as rheumatoid arthritis,66 inflammatory bowel diseases,67 asthma,68 and psoriasis,69 among 
others. Particularly, n-3 PUFA appear able to protect against inflammatory fibrosis, even after the 
inflammatory insult has occurred.70,71 We therefore hypothesized that similar beneficial effects may 
be derived in the settings of TB and TB-IRIS, through incorporation of n-3 PUFA into, and the effects 
of their derivatives on immune cells. In order to test this hypothesis, we investigated a patient-specific 





1.5 Proteomics  
Proteomics is the study of the structure, function, localisation, and abundance of all the proteins in a 
system at a given time. Recently, rapid progress has been made due to technical advances in mass 
spectrometry (MS), facilitating the simultaneous detection, identification, and quantitation of 
thousands of proteins, rather than focusing on a single protein or handful of proteomic markers 
generally investigated by other immunological methods.72 Because proteins perform the end-
functions of the cell, the proteome more directly reflects observable phenotypes than the genome or 
even the transcriptome.73,74 Proteomic complexity derives from differential mRNA processing, splicing, 
degradation, post-translational modifications (PTMs), and targeting to different sub-cellular and 
extracellular compartments. The proteome is hugely varied and dynamic, responding in real time to 
inherent characteristics (such as age and gender) and external factors (such as diet, exercise, and 
exposure to toxins). Clinical proteomics aims to provide clinicians with risk stratification, diagnostic, 
and prognostic tools to facilitate more personalized treatment.72 Research has focused largely on the 
discovery of peripheral biofluid markers for the early diagnosis of chronic diseases such as cancer, but 
also on the discovery of new drug targets. Discovery proteomic analysis must be followed by 
targeted work, to accurately measure the expression of certain key proteins and validate 
potential biomarkers. The work presented here covers only the initial and primary 
investigation in the proteomic pipeline. Here we outline the basic workflow and machinery used 
in MS-based proteomic approaches (Figure 8). 
 
1.5.1 Mass spectrometry 
A mass spectrometer is able to measure ion mass-to-charge ratios (m/z), from which the identity and 
quantity of any ion can, in principle, be deduced. The instrument comprises three main components: 
the ion source, which ionizes analytes into the gas phase; the mass analyzer, which measures m/z; and 
the detector, which counts the number of ions corresponding to each m/z value. Each is these is 
discussed in further detail. 
 
The typical sample processing workflow for bottom-up, MS-based proteomics involves lysis of the 
relevant sample (such as tissue, cells, cell culture supernatant, or biofluid) to extract the proteome. 
Fractions, such as the cell membrane, may be enriched through the use of specific techniques. Proteins 
are then digested enzymatically, usually with trypsin, to yield peptides. The specificity of trypsin 
cleavage allows for prediction of peptide products, which ionize more readily than full proteins. 
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Peptides are injected into the instrument and are further separated by high-pressure liquid 
chromatography (HPLC). This is achieved via reversed-phase chromatography, which uses the 
peptides’ hydrophobicity as a basis for separation, using a C18 octadecyl bonded silica solid phase 
column. This decreases complexity and ensures detection of a greater number of peptides as elution 
of peptides from the HPLC column into the MS is fractionated. 
 
Ionization 
Next, peptides undergo ionization for improved MS detection. The two ionization methods most 
commonly used for proteomics are electrospray ionization (ESI) and matrix-assisted laser desorption 
ionization (MALDI). In ESI, high voltage (2-6 kV) is applied to the peptide solution that is sprayed as it 
elutes from the liquid chromatography column.75 ESI is particularly suited to use in conjunction with 
liquid-based chromatographic methods such as HPLC, and is therefore more commonly used for the 
analysis of complex protein samples. MALDI involves spotting a sample onto a light-absorbing matrix, 
which is then probed with a laser pulse. The matrix absorbs energy from the laser and transfers it to 
the analyte in the sample, which is then ionized into the gas phase.75 MALDI is better suited to low-
complexity samples, but is particularly useful in analyzing tissue or organ sections as the entire section 
can be analyzed at once whilst maintaining spatial distribution of the analytes.76    
 
Mass analyzers 
According to Aebersold et al.,77 the key aspects of the mass analyzer are “sensitivity, resolution, mass 
accuracy and the ability to generate information-rich ion mass spectra from peptide fragments 
(tandem mass or MS/MS spectra)”. There are several kinds of mass analyzers but the three most 
commonly used in proteomics are the ion trap, time-of-flight (TOF), and quadrupole. These can also 
be used in combination. Ion trap mass analyzers ‘trap’ ions for specified time or until a specific 
threshold is reached before releasing them for MS analysis. Although ion traps are sensitive and 
relatively inexpensive, the mass accuracy achieved may be relatively low.77 However, they remain the 
source of most proteomics data in the literature, and an Orbitrap instrument, which uses rotational 
motion of ions around a central spindle, was used in the current study. Strictly speaking, an Orbitrap 
is not considered an ion trap but a mass analyzer, as conventional ion traps do not measure m/z ratios 
but merely allow accumulation of ions before measurement by an analyzer. TOF analyzers are more 
often used in combination with MALDI, as they measure the mass of intact peptides. Peptide ions are 
accelerated through a tube of fixed length and the time taken to reach the detector in subsequent 
field-free drift is measured. This allows the ion’s exact mass to be calculated. Finally, quadrupole mass 
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analyzers make use of four parallel metal rods in between which ions navigate and are stabilized by 
electric fields according to their m/z ratios. In triple quadrupole instruments, ions of a desired m/z 
ratio are selected in the first quadrupole (Q1), before proceeding to a collision cell (Q2). There, high 
pressure, electrical voltage, and collision with neutral gases cause collision-induced dissociation (CID). 
Ion fragments finally proceed to Q3 for identification. Quadrupole mass analyzers are often used for 
the detection/quantification of selected ions of known mass.  
 
MS1 spectra are continually generated as ionized peptides elute into the mass analyzer. If the intensity 
of a particular ion is above a certain threshold, the ion is selected for fragmentation, after which 
further MS spectra (MS2, tandem MS/MS) of the ion fragments will be obtained. Usually, a “top 10” 
approach is employed, where the ten ions with highest intensities in a given time window are selected 
for further fragmentation. In the instrument used in this study, a Q Exactive hybrid quadrupole-
Orbitrap, precursor ion selection is achieved using a quadrupole mass analyzer, with ions accumulating 
in a C-trap before fragmenting in the HCD cell, and high resolution MS2 is produced by Fourier-

































Figure 8. General workflow for mass spectrometry-based proteomics 
a) MS-based proteomics involves lysis of the relevant sample (such as tissue, cells, cell culture 
supernatant, or biofluid) to extract the proteome. b) Proteins are then digested enzymatically, usually 
with trypsin, to yield peptides. The specificity of trypsin cleavage allows for prediction of peptide 
products, which ionize more readily than full proteins. c) Peptides are injected into the instrument 
and are further separated by high-pressure liquid chromatography (HPLC) to decrease complexity and 
ensure detection of a greater number of peptides. d) Peptide ions are detected as MS1 spectra, and 
their m/z ration is determined. e) Selected peptides are fragmented, usually by collision-induced 
dissociation, and fragments are detected at the MS2 level. f) Spectra obtained from precursor and 
fragment ions are matched to those of a spectral database, produced in silico, by software algorithms 
such as MaxQuant to allow for protein identification. Data are then quantified, by the spectral count 
or peak intensity methods (label-free quantitation). g) Finally, biological significance is derived from 
the data through the use of statistical tests, functional classification, and network analyses. (Figure 









1.5.2 Computational processing 
Identification and quantitation 
Identification of proteins from tandem mass spectra is achieved through computational approaches. 
MaxQuant (www.maxquant.org), the free-ware software used in the present study, uses an internal 
search engine, Andromeda, to match experimental spectra with a database of theoretical spectra for 
the in silico-generated, trypsin-digested reference proteome specified.80 This probability-based 
algorithm is similar to that used in Mascot, another popular search engine. To address the issue of 
possible false positive matches, Andromeda assigns a posterior error probability (PEP) score to each 
spectral match, producing a false discovery rate (FDR). This is achieved by comparing peptide-
spectrum matches (PSM) made to a decoy database comprising reverse protein sequences, to 
matches made to a true database.81 
 
Although several stable isotope labelling strategies to enable quantitation of proteins are available 
(such as SILAC82 or iTRAQ83), a label-free quantitation approach was employed in the current study, as 
it remains the simplest, most cost-effective method that can be applied to clinical samples. Technical 
variability must be considered in both approaches, but particularly so in label-free studies. To achieve 
this, technical, as well as biological, replicates must be included in the study design so that this 
variability may be assessed. Label-free quantitation may be achieved by spectral count, which relies 
on the assumption that more abundant proteins produce a greater number of peptides that can be 
identified.84 Furthermore, protein size is considered, as large proteins produce more peptides and 
therefore more MS/MS fragments and detection events. The peak intensity method, implemented 
here via MaxQuant’s MaxLFQ, monitors peptide-specific elution profiles and uses the resulting area 
under the curve to calculate peptide (or pre-cursor ion) abundance.85 In addition, the “match between 
runs” feature in MaxQuant allows unidentified or incomplete spectra in certain samples to be matched 
with identifications in other samples, based on retention times and masses, thereby improving 
identification and quantitation.85  
 
Statistical and biological analyses 
To compare protein abundance between different samples and sample groups, tests may be 
performed to determine statistical significance. Student’s t tests can be applied to compare protein 
expression across two sample groups, while analysis of variance (ANOVA) is used to compare that in 
three or more conditions. In these tests, the mean expression value (in this case, mean LFQ intensity) 
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per sample group, as well as the standard deviation from the mean, are considered, and a p-value is 
calculated. The differences in the mean protein expression between groups are deemed statistically 
significant is p < 0.05 (or other user-defined threshold). Multiple testing correction is applied here 
using the Benjamini-Hochberg method or permutation-based FDR. In the current study, statistical 
analyses were performed using the open-source software Perseus (http://www.perseus-
framework.org).86 
 
Lists of significantly differentially expressed proteins generated here are further analyzed in terms of 
their biological significance using the STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database, freely accessible at http://string-db.org/. STRING incorporates data 
relating to all biologically meaningful protein interactions, both at the direct (physical) and functional 
levels. Knowledge is gathered from experimental evidence, as well as known pathways and protein 
complexes extracted from curated databases, co-expression analysis, genomic data, automated text-
mining, and gene orthology-based interactions.87 Other popular functional classification tools include 
PANTHER (protein annotation through evolutionary relationships), which uses gene ontology, 
pathways, and statistical analyses to probe large-scale genomic or proteomic data,88 and Cytoscape, 














Project rationale, aims, and objectives 
 
2.1 Rationale 
TB-IRIS is an inflammatory disease mediated by the complex and dynamic immune system, and 
physiologically characterised by an increase in several inflammatory molecules. N-3 PUFA are safe and 
effective immune-modulatory agents with inflammation-resolving activity, and we hypothesized that 
they will have beneficial effects on TB-IRIS-associated inflammation. A systems biology approach such 
as MS-based proteomics is an appropriate strategy for investigation of n-3 PUFA-mediated modulation 
of TB-IRIS, as it is a systemic disorder involving the complex immune system. The investigation of the 
proteomic changes induced by n-3 PUFA treatment in TB-IRIS patient-derived PBMCs will provide pre-
clinical rationale for the beneficial effects of n-3 PUFA in the TB-IRIS setting.  
 
2.2 Aims 
The current work aimed to use MS-based proteomic strategies to: 
1) Investigate the effects of re-stimulating healthy donor and IRIS/non-IRIS patient-derived 
PBMCs with Mtb whole cell lysate (WCL) 
2) Investigate the effects of n-3 PUFA pre-treatment on Mtb WCL-stimulated healthy donor 
and patient-derived PBMCs 
3) Identify any differences in the responses of non-IRIS and IRIS patients-derived PBMCs to 
Mtb WCL stimulation and n-3 PUFA treatment 
 
2.3 Objectives 
In order to fulfil the aims, the following objectives were applied: 
 Isolate and cryopreserve PBMCs from healthy donors, optimise a cell culture model to culture 
PBMCs, including re-stimulating with Mtb WCL and pre-treating with n-3 PUFA 
 Perform MS-based, label-free, discovery proteomic analysis on the cell culture supernatants 
from healthy donor PBMCs (n = 3) thawed and rested for 18 h, and then re-stimulated with 
Mtb WCL for 24 h 
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 Repeat the discovery proteomic analysis using cell culture supernatants from healthy donor 
PBMCs (n = 4) thawed and rested for 18 h, pre-treated with n-3 PUFA for 2 h, and then re-
stimulated with Mtb WCL for 24 h 
 Repeat the discovery proteomic analysis using cell culture supernatants from non-IRIS (n = 5) 
and IRIS (n = 5) patient-derived PBMCs thawed and rested for 18 h, pre-treated with n-3 PUFA 
for 2 h, and then re-stimulated with Mtb WCL for 24 h 
 Analyze the data to identify differentially expressed proteins between control and stimulated 








3.1 Cell work 
3.1.1 Healthy volunteer sample collection 
Eight healthy blood donors were recruited from the Blackburn research group (four males and four 
females). Each volunteer filled in a questionnaire to collect relevant metadata (Table 3) and two to 
four vials of blood (18 to 36 mL) were obtained from the cubital vein in heparinised vacutainers. 
 
Table 3. Healthy volunteer characteristics 
ID code Age (years) Sex BCG vaccine Alcohol 
consumption 
Smoker Medication Illness 
HV01 24 Male Yes None No No No 




HV03 38 Male Yes Occasionally Yes No No 
HV04 28 Male Yes Rarely No No Allergies 
HV05 25 Male Yes None No No Asthma 
HV06 29 Female Yes Regularly No No No 
HV07 27 Female Yes None No No No 





Volunteers were asked to complete questionnaires to collect the following data: age, sex, whether 
they had received the BCG vaccine, alcohol consumption and smoking habits, medication taken 





3.1.2 PBMC isolation 
Blood samples were processed in a Bio-Safety Level 2 (BSL2) laboratory within 4 h of collection. The 
standard Ficoll-Paque density gradient centrifugation method was used to isolate PBMCs from whole 
blood.90  
 
Fifteen to 18 mL of blood was diluted with an equal volume of Dulbecco's phosphate buffered saline 
(PBS; Sigma) at room temperature (approximately 23 °C) in a 50 mL tube. Eighteen millilitres of Ficoll-
Paque Plus (GE Healthcare LifeSciences) was placed in a new 50 mL tube, over which an equal volume 
of the blood/PBS solution was gently layered. The mixture was centrifuged at 700 g for 20 min at room 
temperature (brake off). As a result of this centrifugation step, the solution separated into four layers 
(Figure 9): the uppermost layer containing plasma, while the second layer, characteristically milky 
white, contained PBMCs. The third and fourth layers contained Ficoll-Paque media and 
granulocytes/erythrocytes, respectively. 
 
Figure 9. Schematic representation of layers formed after centrifugation 
The uppermost layer contains plasma, while the second layer is characteristically milky white and 
contains PBMCs. The third and fourth layers contain Ficoll-Paque media and 
granulocytes/erythrocytes, respectively. Sourced from GE Healthcare BioSciences, 2014.91 
 
Using a Pasteur pipette, the middle phase containing PBMCs was carefully removed, and added to a 
new 50 mL tube containing 10 mL RPMI-1640 medium (Sigma). The PBMCs were washed by 
centrifuging at 600 g for 10 min at room temperature (brake on). The supernatant was discarded, and 
10 mL RPMI was added to the pellet and triturated to ensure cells were well suspended. A 20-μL aliquot 
was removed for cell counting (see section 3.1.3 Trypan blue exclusion assay (cell counting)) and cells 
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were centrifuged once more as previously. The pellet was resuspended in RPMI containing 10% fetal 
calf serum (FCS, Sigma), and FCS containing 20% dimethyl sulfoxide (DMSO, Sigma) to obtain a 
concentration of 5-6 million cells/mL in 40% RPMI/FCS, 50% FCS/DMSO, and 10% PBS. The solution 
was aliquoted into cryovials and placed in a Mr FrostyTM (ThermoScientific) at -80 °C overnight before 
transferring the following day to a liquid nitrogen tank for long-term storage.  
 
3.1.3 Trypan blue exclusion assay (cell counting) 
In a 96-well plate, a 20-μL PBMC cell suspension aliquot was diluted with 20 μL 0.4% trypan blue 
solution (Sigma). A 10-μL aliquot of the resulting solution was then loaded onto a FastRead 102TM 
counting chamber microscope slide (Hycor Biomedical) and visualized under the microscope. The cells 
in the top 16 blocks of the counting chamber were counted (each block contains a volume of 0.1 μL). 
The total number of cells in the 10 mL PBMC solution was then calculated by multiplying by 2 (as the 
PBMC solution was diluted with trypan blue at a ratio of 1:1), then by 10 (as the volume in which the 
cells are suspended is 10 mL), and finally by 105 (as the volume of each counting chamber block is 0.1 
μL). The formula below (Equation 1. Total number of cells in 10 mL RPMI PBMC solution) was 
used to calculate the number of PBMCs in solution. In addition, the percentage cell viability was 
estimated by counting the number of dead cells which had taken up trypan (seen as blue under 
microscope), dividing by the number of live cells (white), and multiplying by 100. 
 
Equation 1. Total number of cells in 10 mL RPMI PBMC solution 
Number of PBMCs = total cells counted in 16 blocks x 2 x 10 x 105 
   
 
3.1.4 Thawing 
To thaw, cryovials containing frozen PBMCs were removed from the liquid nitrogen tank and 
immediately placed on ice after loosening caps. The samples were then thawed in a water bath at 37 
°C until a small block of ice remained in the tubes, and were moved to a BSL2 cabinet for further 
processing. Five hundred microliters of warmed (37 °C) RPMI medium was added dropwise, and the 
cells were then transferred to a 15 mL tube containing 5 mL warmed medium. One millilitre of medium 
was used to rinse out the cryovials and added to the rest of the cells. The freezing medium containing 
10% DMSO was exchanged for RPMI by pelleting cells at 500 g for 5 min (20-25 °C) and discarding the 
supernatant. This wash step was repeated. The cells were then resuspended in 2 mL RPMI containing 
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1% penicillin/streptomycin (pen/strep) solution, and counted (see section 3.1.3 Trypan blue exclusion 
assay (cell counting)). Another 3 mL of RPMI was added to the cells, which were then rested overnight 
at 37 °C in a 5% CO2 atmosphere to ensure lysis of any apoptotic cells.  
 
3.1.5 Cell culture 
Following overnight rest, the cells were pelleted at 500 g for 5 min at room temperature, resuspended 
in 1 mL RPMI supplemented with 1% pen/strep solution, and counted (see section 3.1.3 Trypan blue 
exclusion assay (cell counting)). Suspension volume was adjusted with RPMI to obtain a concentration 
of 106 cells/mL. Cells were cultured in 24-well, flat-bottomed cell culture plates with lids (Costar, 
Corning) at a concentration of 5 x 105 cells per well. Cells were plated as follows: RPMI was added to 
all wells first, followed by 1 μL EPA (Sigma) and 1 μL DHA (Sigma), both made up in ethanol to 100 µM 
stocks, or 2 μL ethanol (Sigma), added to the treatment and vehicle control wells respectively, and 
finally 500 μL of cell suspension. Cells were then pre-incubated in the presence of EPA and DHA for 2 
h, before the addition of 20 μL Mtb lysate (whole cell lysate (WCL) from H37Rv, 2 μg/mL) into the 
relevant wells. Incubation was then continued for a further 24 h. The volumes of all reagents used are 
shown in Table 4. Volume of each reagent added to cultured PBMCs 
  




Control Mtb control Vehicle control PUFA treatment 
RPMI  500 480 478 478 
EPA/DHA  - - - 2 
Ethanol  - - 2 - 
Mtb WCL  - 20 20 20 
Cell suspension  500 500 500 500 





3.1.6 MTT viability assay 
PBMCs were thawed and rested overnight according to methods described in section 3.1.3 Trypan 
blue exclusion assay (cell counting). Cells were then plated according to the method described in 
section 3.1.4 Thawing. For this experiment, three healthy volunteer samples were used and plated in 
triplicate for each condition. 
 
After overnight incubation, the culture medium was removed from each well and replaced with 500 
μL warmed PBS (37 °C) to wash off any cellular debris. The PBS was then removed and 1 mL medium 
containing MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) was 
added to each well (0.5 mg/mL). The plate was briefly shaken on vortex before incubating for 30 min 
at 37 °C. The plate was visualized under microscope to check for the presence of purple formazan 
precipitate in the cells. The supernatant was removed, replaced with 300 μL DMSO, and triturated to 
dissolve formazan crystals. The plate was vortexed briefly before incubating for 10 min. Finally, the 
contents of each well were transferred to a 96-well plate containing blanks (RPMI processed in parallel 
using the same method) for analysis on the microplate reader (Bio-Rad). Absorbance was read at 560 
nm. Wells containing untreated cells were used as positive controls. 
 
Cell viability was calculated as a percentage by subtracting the mean absorbance of the blank from 
each sample absorbance, dividing by the mean absorbance of the control minus the mean absorbance 
of the blank, and multiplying for 100 (see Equation 2. Percentage cell survival). 
 
Equation 2. Percentage cell survival 
% cell survival = (sampleabs − blankabs)/(controlabs − blankabs) × 100 
 
 
3.2 Sample preparation for MS-based proteomic analysis 
3.2.1 Collection of cell culture supernatants 
After a 24-h incubation period, 1 mL culture supernatant was transferred to 1.5 mL tubes and 
centrifuged at 500 g for 5 min to pellet any detached cells and cellular debris. The supernatant was 





3.2.2 Sample preparation 
Bicinchoninic acid (BCA) assay for protein quantitation 
Frozen supernatant samples were retrieved from the -80 °C freezer and left to thaw on the bench. The 
samples were taken through two cycles of boiling (at 95 °C for 3 min) and sonicating (3 min), followed 
by filtration through 0.2 μm filters to remove any cells or cellular debris. Protein concentration was 
quantified by micro-BCA protein assay (Thermofisher Pierce BCA protein assay kit) according to the 
manufacturer's instructions. Briefly, bovine serum albumin (BSA) standards were prepared by serial 
dilution with RPMI to obtain the following five concentrations: 1, 0.5, 0.25, 0.125, and 0.0625 mg/mL. 
The working reagent was prepared by adding 392 μL of Solution B to 19 mL of Solution A. Twenty-five 
microliters of samples and standards was plated in a 96-well plate, and 200 μL of working reagent was 
added. The plate was covered with parafilm and shaken on vortex, before incubating at 37 °C for 30 
min. The plate was cooled to room temperature (20-25 °C) and absorbance was read at 560 nm on 
microplate reader (Bio-Rad).  
 
Filter-aided sample preparation (FASP) 
Reagents used for FASP were made up fresh every time (urea buffer, iodoacetamide, and ammonium 
bicarbonate). Dithiothreitol (DTT, see Appendix A for preparation) was added to each sample at a ratio 
of 1:4, and samples were incubated for 30 min at room temperature (20-25 °C). Two different 
molecular weight cut-off FASP filters (Amicon Ultra 0.5 mL, 10 kDa and 3 kDa size exclusion filters, 
Merck Millipore) were tested for comparison. All filters were first washed with 500 µL 8M urea buffer 
(UA, see Appendix for preparation) and centrifuged at 15,000 g for 10 min. FASP filter tubes were 
placed in the centrifuge with hinges facing towards the rotor, and this orientation was maintained 
throughout every spin. The flow-through was discarded. Samples was loaded onto each filter, and 200 
μL UA added before centrifuging again at 15,000 g for 15 min. The samples were then washed with 
200 μL UA and centrifuged for 10 min at the same speed, and the spin was repeated twice until flow-
through was no longer bubbly. The flow-through was moved to waste eppendorfs and stored in case 
protein was lost during processing and needed to be recovered at a later stage. The samples were then 
alkylated by adding 100 µL 0.5 M iodoacetamide (IAA, see Appendix for preparation), shaking on vortex 
for 1 min and incubating for 20 min in the dark. The excess IAA was then washed off by centrifugation 
at 15,000 g for 10 min, before doing three washes with 200 µL UA and 15 min centrifugation steps. 
The pH of the samples was then increased by adding 100 µL 0.05 M ammonium bicarbonate (ABC, see 
Appendix for preparation) and centrifuging twice at 15,000 g for 10 min each time. Filters were then 
moved to new eppendorfs for elution the following day, and flow-through was again stored. For trypsin 
digestion of samples, 25 µL of 2X Trypsin-Ultra Reaction buffer (see Appendix for contents) was added. 
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Five microliters of Trypsin-Ultra (see Appendix for preparation) was added to each sample before 
shaking on vortex for 1 min. The pH was checked using MColourpHast pH indicator strips (Merck 
Millipore) and adjusted with ABC if necessary to obtain a pH of 8. Samples were placed in a wet 
chamber and incubated at 37 °C for 18 h.  
 
After incubation, samples were removed from the wet chamber and centrifuged at 15,000 g for 10 
min. Eppendorfs were placed in the centrifuge with hinges facing away from the rotor (opposite 
orientation as the previous day) and were kept in this orientation throughout spins. Forty microliters 
ABC was added and samples were centrifuged again at 15,000 g for 10 min. To acidify peptides, 50 µL 
solution A (2% acetonitrile (ACN), 0.1% formic acid (FA) in MS-grade H2O) was added before 
centrifuging for 10 min at 15,000 g. This step was repeated twice with 50 µL solution C (60% ACN, 0.1% 
FA) added each time. The pH was checked using pH strips and adjusted with 0.5 µL formic acid if 
necessary to obtain a pH of 2-3. In order to confirm that peptides had successfully eluted, each FASP 
filter was placed upside down in the corresponding waste eppendorf and centrifuged at 15,000 g for 
10 min. The flow-through was checked for pellets, as the presence thereof would indicate that the 
sample protein/peptides had remained on the filter instead of eluting through as desired. If no pellet 
was seen, samples were taken forward for desalting.   
  
Desalting 
Tryptic peptides were desalted using 3M Empore Octadecyl C18 SPE disks (Supelco) following an in-
house protocol. Extraction disks were first equilibrated three times by adding with 100 µL solution B 
(80% ACN, 0.1% FA in water) and centrifuging for 1-2 min at 3000 g. This was followed by two washes 
with 100 µL solution A, centrifuging 1-2 min at 3000 g as before. Twenty micrograms of peptides was 
then loaded and washed three times with 50 µL solution A. The flow-through was moved to waste 
eppendorfs, and desalted peptides were then eluted into tapered glass inserts by washing three times 
with solution C. Finally, peptides were vacuum-dried until 1-2 µL of solution was left and resuspended 
to a concentration of 1 µg/µL with 20 µL solution A. This stock solution was further diluted to 200 
ng/µL for analysis on a Q Exactive hybrid quadrupole-Orbitrap mass spectrometer (Thermo).   
 
Methanol/chloroform precipitation 
Frozen supernatant samples were retrieved from the -80 °C freezer and thawed at room temperature. 
Samples were transferred to amber vials, and methanol was added to the sample at a ratio of 1:1, and 
chloroform at a ratio of 3:4. The resulting solution was mixed by swirling and then centrifuged at 4000 
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g for 5 min. The upper phase containing chloroform was carefully removed by pipetting and stored in 
eppendorfs at -20 °C for future lipidomic processing. The interphase containing proteins was mixed 
with the lower phase and further methanol was added at a ratio of 3:4. The solution was again mixed 
and centrifuged as before. The supernatant was removed and discarded and the resulting pellet was 
left to air-dry in a fume hood for 1 h. Once dry, the protein pellets were resuspended in 50 µL 
denaturation buffer (see Appendix A for preparation), transferred to eppendorfs and stored at -20 °C 
until further processing. 
 
Modified Bradford assay for protein quantitation 
Protein was quantitated using the Bio-Rad Protein Assay (Bio-Rad), according to the manufacturer's 
instructions. This assay is specifically modified to quantitate protein in urea-containing buffer. Briefly, 
1 mL of Bio-Rad Bradford reagent was diluted with 4 mL distilled water, and BSA standards were serially 
diluted with denaturation buffer to obtain five standards at the following concentrations: 1, 0.5, 0.25, 
0.125, and 0.0625 mg/mL. The assay was done in a 96-well flat-bottomed plate, with each well 
containing 90 µL 0.1 M HCl, 150 µL Bradford reagent, and 1 µL sample, added in this order. The 
absorbance was read at 595 nm on a microplate reader (Bio-Rad). 
 
In-solution protein digestion 
One microliter of 1 M DTT reduction buffer (see Appendix A for preparation) was added to the samples 
at a final concentration of 1 mM before incubating for 1 h at room temperature. IAA alkylation buffer 
was then added to a final concentration of 5.5 mM, and samples were incubated for 1 h at room 
temperature in the dark. Samples were then diluted with four volumes of 50 mM ABC. Trypsin-Ultra 
was added at a ratio of 1 µg Trypsin to 50 µg sample protein, and incubated overnight for 19 h at room 
temperature. After overnight incubation, the reaction was stopped by adding 1 µL FA and the pH was 
checked to be between 2 and 3. Samples were then taken forward for desalting, following the method 
described in 3.2.2 Sample preparation  
 
3.3 LC-MS/MS analysis parameters  
Discovery proteomic analysis was performed on a Q Exactive Quadrupole-Orbitrap mass spectrometer 
(Thermo Scientific), coupled with a Dionex UltiMate 3500 RSLC nano-LC system (Thermo Scientific). A 
standardised LC gradient, developed in our laboratory for use with mammalian peptide extracts, was 
used. One microliter of sample (0.5 – 10 µg) was injected onto a trap column packed in-house with 
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Luna C18 coated silica beads (75 µm x 2 cm fused silica: New Objective; 5 µm Luna C18 resin: 
Phenomenex). Separation was performed by reversed phase chromatography on a nanoscale 
analytical column, also packed in-house (5 µm Luna C18 beads, 75 µm x 20 cm). Solvent A comprised 
0.1% FA (LC-MS Ultra, Eluent Additive, Sigma) in HPLC grade H2O (LC-MS Ultra, Sigma), while Solvent B 
comprised 0.1% FA (LC-MS Ultra, Eluent Additive) in ACN (LC-MS Ultra, Sigma). Samples were eluted 
using a non-linear gradient at a constant flow rate of 400 nL/min, with solvent B increasing from 6 to 
35% over 60 min (12 to 72 min), and from 35 to 80% over 5 min. Twenty-five minutes equilibration and 
wash (0 to 12 min, and 77 to 90 min) were also included.  
 
Discovery mode data acquisition by the Orbitrap was performed in ‘Top 10’, data-dependent, positive 
ion mode. MS1 settings included resolution at 70 000, automatic gain control (AGC) target of 3e6, and 
a maximum injection time of 250 ms. At the MS2 level, resolution was set at 17 500, AGC target of 1e5, 
ion injection time of 80 ms, isolation window of 2.0 m/z and a normalised collision energy (NCE) of 28. 
Oxidation (variable) and carbamidomethylation (fixed) were included as modifications.  
 
3.4 Data analysis 
3.4.1 Database search  
RAW files were submitted to the free-ware software MaxQuant v.1.5.2.8 
(http://www.biochem.mpg.de/5111795/maxquant) for protein identification and label-free 
quantification. The UniProt human and Mtb H37RV proteomes (FASTA files) were used for database 
search (downloaded 2 Feb 2017; human, 71,775 proteins; Mtb, 3993 proteins). Carbamidomethylation 
was set as a fixed modification, and methionine oxidation and N-term acetylation as variable 
modifications. The following parameters were used: PSM, protein, and site FDR, 1%; MS/MS tolerance, 
20 ppm; matching time window, 0.7 min; alignment time window, 20 min. The “match between runs” 
setting was selected to increase the probability of identifying protein groups in all samples and to aid 
in the comparison of protein group quantities across samples. MS data quality and summary statistics 
were assessed in the R environment using scripts developed in-house. 
 
3.4.2 Data processing 
Data processing was done via the open-source software Perseus v1.5.5.3 
(http://www.biochem.mpg.de/5111810/perseus). The ProteinGroups file produced by the MaxQuant 
search was loaded onto a new session in Perseus. The protein list was filtered to remove all protein 
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groups labelled “Contaminants”, “Reverse”, “Only identified by site”, as well as those identified with 
only one unique peptide (Filter rows -> Based on categorical column, and filter rows -> Based on 
numerical value -> Unique peptides > 1). The data were then transformed by log2(x). In order to 
impute missing values, the distribution of the protein intensities was evaluated by looking at the 
histograms (Visualization -> Histogram) and these were exported to .pdf. Missing values were then 
imputed from the normal distribution (w = 0.3, downshift = 1.8). Rows were then annotated into the 
condition groups (Annot. Rows -> Categorical annotation rows). Since the protein list contained both 
human and Mtb proteins, we used the “Find” function to export lists of human-only proteins and Mtb-
only proteins. Using the human-only list, principal component analyses were carried out (Clustering -
> Principal component analysis) and resulting figures were exported to .pdf. Differential expression 
analysis was performed by hypothesis testing, using paired two-sampled t-tests (p < 0.05) for each 
protein group in order to identify differentially expressed protein groups. Permutation-based FDR 
multiple testing correction was applied at the 5% level. The resulting protein list was filtered to retain 
only those with a significant t-test score (p < 0.05). The final significant protein lists were visualized as 
volcano plots (Misc -> Volcano plot). Volcano plots and protein lists were exported to .pdf and .txt 
files, respectively. Other data visualizations include multi-scatter plots and heat maps. Venn diagrams 
were produced using the open-source software VennDIS (available at 
http://kislingerlab.uhnres.utoronto.ca/projects/VennDIS_v1.0.1.zip).  
 
3.4.3 Biological significance analysis 
Functional classification and gene annotation were performed using the free online database STRING 
(http://string-db.org), and the free software FunRich (www.funrich.org).  
 
 








With the experiments described in this chapter, we aimed to optimise the cell culture platform and 
ensure that cell isolation, preservation, and culture conditions were appropriate for cell survival. 
PBMCs were isolated from freshly drawn blood and cryopreserved in liquid nitrogen at ultra-low 
temperatures. We investigated the recovery rates of cryopreserved (c-)PBMCs after thawing, as well 
as survival rates after overnight rest and after stimulation with Mtb whole cell lysate (WCL) and 
treatment with PUFA through trypan blue exclusion and MTT assays. 
 
4.2 Introduction 
4.2.1 PBMC analysis 
The investigation of the immune system is at the heart of understanding the pathogenesis of many 
immune disorders such as rheumatoid arthritis, multiple sclerosis, and of course, TB-IRIS. Analysis of 
PBMCs is particularly relevant as it allows for the investigation of the role and phenotype of a 
heterogeneous population of immune cells, including monocytes and lymphocytes.92 TB-IRIS is 
reportedly associated with hypercytokinemia,50 as well as heightened Th1 cell responses,48 and we 
therefore hypothesized that TB-IRIS-specific cell responses would be reflected in the proteome of 
patient-derived PBMCs. 
 
With access to ex vivo PBMCs from HIV-positive and TB-infected patients, some of whom developed 
TB-IRIS (“IRIS group”) and some of whom did not (“non-IRIS group”), we aimed to re-stimulate the 
cells in vitro and treat them with n-3 PUFA before harvesting the culture supernatants to investigate 
the secretome. Before analyzing clinical samples, the various cell culture methods were optimised 
using healthy volunteer (HV) PBMCs. The workflow includes collection of PBMCs, re-stimulation and 
treatment, sample processing for proteomic analysis via LC-MS/MS, followed by statistical and 








Figure 10. Infographic of the methodology used 
1. PBMC collection, 2. cell culture, and 3. sample processing for proteomics.  
 
4.2.2 PBMC re-stimulation with Mtb WCL 
Isolated ex vivo PBMCs can be treated or stimulated with bacterial or viral products to investigate the 
resulting immune response. In this study, we assessed the proteomic changes induced in the PBMC 
secretome by re-stimulation with Mtb WCL. To this end, healthy donor PBMCs were isolated and 
cryopreserved. As required, these cells were then thawed, rested, and re-stimulated with H37Rv Mtb 
cells lysed with Triton X-100 for 24 h. Tadokera et al.50 used a similar method, but re-stimulated PBMCs 
with heat-killed H37Rv Mtb. Other methods include re-stimulation with PPD, ESAT-6, and 
Antigen85B46, or ESAT-6/CFP10 fusion protein.49 In this study, we have used WCL from H37Rv bacteria 
for practical reasons as this was easily available to us. We used a concentration of 2 μg/mL, as did Hoft 
et al.93 Mtb WCL contains cell surface antigens, as well as intracellular products, which are likely to 
elicit an immune response from PBMCs.  
 
4.2.3 n-3 PUFA treatment 
PBMCs were also subjected to n-3 PUFA treatment to investigate the effects of n-3 PUFA on the Mtb-
activated immune response in PBMCs. In this study, we used a combination of eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), the two most potent n-3 PUFA in humans. A dose-response 
viability assay was performed to assess the effects of three increasing n-3 PUFA concentrations on cell 
viability, and an appropriate treatment concentration was then chosen for further assays. Both EPA 






























4.3 Results and discussion 
4.3.1 Cell recovery  
As part of the cell culture protocol optimisation, healthy volunteer PBMCs were counted at the point 
of freezing, after thawing, and after overnight rest, in order to evaluate the viability of c-PBMCs in 
serum-free conditions. PBMCs were cultured in RMPI-1640 medium not supplemented with serum, as 
the over-abundance of albumin in serum relative to other proteins would have hampered down-
stream proteomic analysis.  
 
 
PBMCs from three healthy volunteers were isolated from whole blood and frozen in liquid nitrogen. 
Cells were later thawed, and rested overnight in culture conditions. Cells were counted at each of 
these two stages, and the number of viable cells recovered was calculated relative to the number of 
cells frozen, and expressed as a percentage. This experiment was repeated several times, and included 
both biological and technical triplicates. Results are shown in Figure 11. The mean recovery ± SD across 
all biological and technical replicates was 38.86 ± 6.81% after thawing, and 36.97 ± 4.02% following 
overnight rest. This indicates that approximately 60% of cells were lost during the freezing period, and 
that overnight rest in serum-free conditions was well tolerated as only a small number of cells 
(approximately 1%) were lost over this period. Viability as assessed via trypan blue exclusion assay 
was > 90% both directly after thawing and after overnight rest. 
 
 
The recovery rate for our frozen PBMCs was slightly lower than that reported in the literature (50-70% 
average yield reported94,95). This could be due to sub-optimal freezing or thawing conditions and 
protocols. However, Nazarpour et al.96 compared the effects of several variables on the yield and 
viability of c-PBMCs, and concluded that the optimal concentrations of DMSO and FCS to be used were 
10-15% and 40%, respectively. In this study, PBMC were stored in a solution containing 10% DMSO 
and 44% FCS. Our thawing process, which includes the addition of warmed medium to the cells to 
dilute the freeze solution containing DMSO, is also in line with current protocols. Ramachandran et 
al.97 showed that “warm processing” produced higher yields of viable cells than “cold processing” 
(adding chilled medium to cells). In our study, the DMSO is washed off immediately when the cells are 
thawed as prolonged exposure can cause cell toxicity; however, Ramachandran et al. showed that c-
PBMCs can withstand up to 30 min exposure to DMSO without losing CD4+ or CD8+ T cell 
functionality.97 Finally, we followed the recommendation by Ramachandran et al. to perform two 
wash steps to remove or dilute DMSO.97 Perhaps cell yields could be increased by cooling the freeze 
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medium to 4 °C before adding to the cell solution, as was recommended by Nazarpour et al.,96 as the 
medium was added at room temperature in our study. 
 
 
The cells were rested overnight to allow for lysis of any apoptotic cells. This is supported by Kutscher 
et al.,98 who showed that c-PBMCs that were not rested overnight contained higher percentages of 
apoptotic cells than rested PBMCs, which contained more dead cells. Another study found that resting 
PBMCs presented no advantage when performing ELISPOT assays.99 In our study, overnight rest did 
not cause significant cell loss and could possibly be avoided in the future although we would first need 














Figure 11. Number of cells recovered after thawing and overnight rest 
Results are shown as means ± SD (error bars) from five independent experiments using cells from 
three healthy donors. 
 
 
4.3.2 Cell viability 
We performed an MTT assay to assess the viability of cells after 24-h incubation with Mtb WCL, 
ethanol (vehicle control), and EPA/DHA treatment. Frozen PBMCs were thawed, rested overnight, and 
plated at a concentration of 5 x 105 cells per well, pre-treated with ethanol or n-3 PUFA, and re-
stimulated with Mtb WCL. We used concentrations of 100 μM EPA and DHA, and 2 μg/mL Mtb WCL. 
The EPA/DHA concentration used was based on the literature (50 to 100 μM100,101,102) as well as 
previous in-house experiments, and a dose-response MTT assay was performed to assess the effects 



























































only on the literature: Bourgarit et al.46 re-stimulated PBMCs with 1 μg/mL PPD and ESAT-6, and 2 
μg/mL 85B, while Skolimowska et al.103 used 5 μg/mL PPD and other Mtb antigens at 10 μg/mL. Finally, 
heat-killed H37Rv has been used at an MOI = 1 in several studies50,103 or MOI = 5.104 Hoft et al.93 used 
whole Mtb WCL at 2 μg/mL to re-stimulate PBMCs, and this is the concentration we also used. 
 
After 24-h incubation, the MTT assay was carried out according to the standard method.105 Percentage 
viability was calculated relative to the untreated and unstimulated control. The results are shown in 
Figure 12 below. There was no significant change in viability in the cells stimulated with Mtb WCL, or 
treated with ethanol and n-3 PUFA. Cell viability was consistently >85% for stimulated and treated 
cells. The results obtained from this assay were confirmed via trypan exclusion assay, which showed 
viability >98% in the unstimulated and untreated control. These results show that neither the serum-











Figure 12. Percentage cell viability for each treatment condition 
Results presented are means ± SD (error bars) from two independent experiments with samples plated 
in biological triplicates. Control: untreated unstimulated cells, Mtb only, cells stimulated with 2 μg/mL 
Mtb WCL; Mtb + vehicle, cells pre-treated with 0.2% ethanol for 2 h and stimulated with 2 μg/mL Mtb 
WCL; Mtb + PUFA, cells pre-treated with 100 μM EPA and DHA for 2 h and stimulated with 2 μg/mL 



















































PUFA dose-response assay 
We performed an MTT assay to assess the effects of increasing n-3 PUFA concentrations (50, 100, and 
200 μM) on cell viability. Viability was greater than 90% at each concentration (Figure 13). The final n-
3 PUFA concentration used for treatment was 100 μM EPA and DHA, and this is in line with the 








Figure 13. Percentage cell viability after 24-h treatment with increasing PUFA concentrations 
Results presented are means ± SD from two independent experiments with samples plated in 
biological triplicates. Three PUFA doses were tested: 50, 100, and 200 μM. There were no significant 
differences in cell viability between any of the treatments (p > 0.05). 
 
4.4 Conclusion 
We developed a cell culture platform to assess the effects of n-3 PUFA treatment and Mtb re-
stimulation of donor-derived c-PBMCs. The cells can be cultured in serum-free conditions for 48 h and 
viability was not affected by PUFA or ethanol pre-treatment, or re-stimulation with Mtb WCL. This cell 
culture protocol is compatible with down-stream MS-based proteomic analysis, as no serum is used. 
With this, the effects of various agents on the PBMC proteome can be assessed in healthy donor cells 
or patient-derived cells in the context of various diseases. We preferred to use whole PBMC 
populations rather than separate cells into distinct groups as we believed this is a better in vitro 
representation of the complex immune system, although it would also be possible to separate out cell 








































Secretome analysis of Mtb-stimulated healthy volunteer PBMCs  
 
5.1 Aim 
The experiment described in this chapter was designed to test the sample processing methods, and 
to evaluate technical and biological variation, as well as reproducibility. To this end, PBMCs isolated 
from three healthy donors were cultured and re-stimulated with Mtb WCL. Unstimulated cells were 
used as controls. In addition to the three biological replicates, all cells were plated in triplicate 
(different wells) to produce three technical replicates for each biological replicate and treatment 
condition. The cell culture supernatants were collected after 24 h and processed for MS-based 
proteomics analysis by chloroform/methanol precipitation followed by in-solution digestion with 
trypsin and desalting on C18 stage tips. Samples were analyzed on a Q Exactive hybrid Orbitrap mass 
spectrometer and peptide and protein identification were performed using MaxQuant. Data were 
analyzed using Perseus. 
 
5.2 Introduction 
5.2.1 Studying the cellular secretome 
The “secretome” refers to the set of molecules produced and secreted by cells, although the more 
modern definition also includes molecules that are shed from the cell’s surface106. Secreted proteins 
are of particular interest as they are responsible for intracellular signalling and interactions. In the 
cancer field, proteins secreted by tumours are often useful as biomarkers. Proteomic profiling of 
cellular secretomes is notably challenging for several reasons as highlighted by Markakis et al.,106 
including (i) the presence and over-abundance of serum proteins such as bovine serum albumin in cell 
culture media, (ii) contamination by non-secreted cytoplasmic proteins as a result of cell death, and 
(iii) very low concentrations of secreted proteins in body fluids such as plasma and urine, or cell culture 
media. Brown et al.107 have stated that secretomic analyses from mammalian cells generally identify 




(i) Serum-free culture conditions 
The problem of serum protein contamination is generally circumvented by culturing cells under 
conditions of serum starvation in serum-free culture medium. However, it is important to consider the 
effect of serum starvation on cellular survival: proliferation rate may be reduced108 and apoptosis 
pathways may be switched on by the metabolic stress of serum starvation.109 On the other hand, 
survival pathways may be activated, especially in the case of tumour cells.110 Levels of cytosolic 
proteins, such as beta-actin and beta-tubulin can be monitored to assess cell autolysis in serum-free 
conditions.111 For long-term cell culture (> 24 h), cells can initially be maintained in serum-
supplemented medium before washing thoroughly to remove medium and switching to serum-free 
conditions for the last 12-48 h of the experiment. In this study, PBMCs were maintained in RPMI-1640 
medium not supplemented with serum for 24 h.  
 
(ii) Concentrating secreted proteins 
Proteins secreted in cell culture medium or body fluids are highly diluted, and usually require 
concentration before mass spectrometry-based analysis. Classical concentration methods include 
precipitation using trichloroacetic acid (TCA), chloroform/methanol, or acetone, as well as 
ultracentrifugation on molecular weight cut-off filters (for example, 10 or 30 kDa). According to 
Makridakis et al., precipitation with TCA supplemented with 0.01-0.1% sodium deoxycholate or 
sodium lauroyl sarcosinate significantly increased precipitation yields and allowed for the enrichment 
of low-abundance proteins such as cytokines from bladder cancer cells.112 In this study, we assessed 
concentration on 10 and 30 kDa FASP filters, as well as chloroform/methanol precipitation followed 
by in-solution digestion. 
 
5.3 Results and discussion 
5.3.1 Sample processing optimisation 
Two sample-processing methods were tested for the proteomic analysis of cell culture supernatants: 
FASP and precipitation with chloroform/methanol coupled with in-solution digestion. Both methods 







After protein quantitation via modified Bradford assay, samples were processed using 10 and 30 kDa 
FASP filters. MS analysis showed that most proteins were lost during FASP and protein identification 
using a database search was impossible. The starting amount of protein was less than 10 µg, which 
would explain the poor results obtained via FASP as this method is not suited to use in samples with 
low protein concentration. We therefore tested the alternative chloroform/methanol precipitation 
method. Proteins in the supernatants were first precipitated by mixing with chloroform and methanol, 
concentrated by air-drying, and subsequently resuspending in a small volume. This method was 
particularly well-suited here as protein concentration in supernatants was so low. Reconstituted 
proteins were then reduced with DTT, alkylated with IAA, and digested in solution with trypsin 
overnight. Digested peptides were desalted as previously the following day on C18 stage tips. 
 
5.3.2 Technical reproducibility of protein quantitation 
Total protein was quantified via modified Bradford assay113 (Figure 14). Cell culture supernatants from 
unstimulated samples contained between 1.85 and 2.15 µg total protein (mean concentration: 0.040 
µg/µL), while stimulated samples yielded between 3.75 and 4.20 µg protein (mean concentration: 
0.079 µg/µL). Stimulated supernatants contained more protein than their unstimulated counterparts 
partially because Mtb WCL was added to these samples at a concentration of 2 µg/mL (total protein 
added: 2 µg). In addition, stimulated cells are likely to produce more protein in response to the 
perturbation experienced. Very similar protein concentrations were obtained from both the technical 
replicates as illustrated by the small standard deviations (error bars), and the biological replicates. This 
indicates that technical and biological variability with regards to protein content in cell culture 
































Data are presented as means ± SD (error bars) of three technical replicates. HV, healthy volunteer. 
 
5.3.3 Technical reproducibility of MS spectra 
Processed samples were initially injected on a Q Exactive LC-MS/MS at 200 ng/µL (1 μL injection 
volume), and we subsequently re-submitted any sample with a total ion chromatogram (TIC) that was 
too high or too low (target: 4e9 to 5e9). The injection volumes were then adjusted to ensure 
consistency of TIC intensities across samples.  
 
The technical replicates for unstimulated samples performed well and were very similar to each other 
in terms of shape of the TIC and retention time for individual peaks: the peak eluting at 83.96 min in 
all samples (Figure 15, Figure 16, and Error! Reference source not found.) is very consistent, as are 
sample-specific peaks, such as peaks eluting at approximately 46 min in the control samples from 
HV01 (Figure 15), or the peak at approximately 57 min in the Mtb-stimulated samples from HV06 
(Figure 17). Samples from HV04 (Figure 16) performed somewhat differently from the other volunteer 
samples, and produced ‘flat’ spectra with a large wide peak at approximately 58 min. This suggests 
poor protein extraction, digestion, or desalting. The sharp peak at 84 min, although it is also seen in 
other samples, could be greater in intensity and therefore responsible for suppressing the signal from 
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Figure 17.  MS chromatogram overlay (TIC) of the unstimulated control samples (HV06, technical 
replicates) 
 
Technical replicates of stimulated samples (Figure 18, Figure 19, and Figure 20) also performed 
constistently as shown by the similar retention time of peaks at approximately 53 min in Figure 18 and 
54 min in Figure 19, and 57 min in Figure 7. However, the chromatogram in Figure 18 shows poor spray 
at 70 to 80 min, resulting in jagged peak lines. Unfortunately, due to time constraints we could not re-
inject this sample. Overall, we concluded that the variability between biological and technical 
replicates in terms of TIC shape was low. 
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5.3.4 Data quality 
Protein identification 
The quality of the MS data and MaxQuant peptide identifications were assessed in the R environment 
using a script developed in-house. A total of 1096 protein groups were identified by MaxQuant using 
its built-in search algorithm Andromeda and the proteomic libraries for Homo sapiens and H37Rv from 
Uniprot. A total of 571,815 spectra were submitted to MaxQuant for analysis, of which 72,243 
(12.63%) were matched to peptides in the database. Although the percentage spectra identified is 
low, it is similar to other experiments performed within our research group on PBMCs, neutrophils, 
and monocytes (unpublished). The number of spectra identified did increase in subsequent 
experiments involving a greater number of samples. 
 
A data quality analysis was performed using MS-GF+ IDPicker. This analysis revealed the number of 
protein groups identified per sample (summarized in Table 5 below). There were approximately twice 
as many protein groups identified in the stimulated samples as in the unstimulated samples. This is 
due both to the Mtb proteins added, and to the increase in human secreted protein. The percentage 
coefficient of variation (CV) shows that the number of protein groups identified and distinct peptides 
varied more in the unstimulated samples than in the stimulated samples. This could suggest that cells 
responding to a stimulus tend to behave more similarly than cells that are not responding to a specific 
perturbation factor, and this hypothesis is also supported by further results. 
 







The tryptic digestion efficiency was similar to that usually achieved when performing in-solution 
digestion within our research group, i.e., 56.3% no missed cleavages, 34.4% with one missed cleavage, 
and 9.3% with two missed cleavages (Figure 21). This was also improved in subsequent experiments 
by adjusting the concentration of trypsin. 
 
Condition Mean ± SD 
protein groups  
% CV Mean ± SD 
distinct peptides 
% CV 
Unstimulated 438 ± 121 27.63 1440 ± 662  45.98 










Figure 21. Tryptic digestion efficiency (missed cleavages) 
 
Protein identification correlates 
After visual inspection of the spectra, the protein groups identified were loaded to Perseus for further 
analysis. A total of 1096 protein groups were identified, of which 842 were left after excluding proteins 
only identified by site, reverse hits, potential contaminants, and proteins identified with fewer than 
two unique peptides. Of these, 549 were Mtb proteins and 293 were human proteins. Total protein 
intensities were then transformed by log2 and histograms were visualized to assess the distribution 
of the data (Figure 22). The data are primarily normally distributed, with some positive skewing 
(skewed to the right).  
  
Figure 22. Distribution histograms of log2-transformed protein intensities  
log2 protein counts were plotted to assess data distribution. Left to right: stimulated HV01, HV04, and 
HV06, and unstimulated HV01, HV04, and HV06 samples. Top to bottom: technical replicates for each 




























Scatter plots and R2 values were generated for each set of technical replicates. The Pearson correlation 
coefficients for unstimulated replicates were between 0.756 and 0.953 ( 
Figure 23). The replicates from HV04 performed the least consistently, as predicted by the poor 
spectra (Figure 16). Technical replicates from HV06 performed the most consistently with Pearson 
correlation coefficients of 0.943, 0.951, and 0.953.  
 
Figure 23. Scatter plots showing correlation between protein groups identified in unstimulated 
technical replicates  
log2 protein expression values from each experimental sample were plotted against those from other 
experimental samples. Numeric values at the top of each graph indicate the Pearson correlation 
coefficient for each comparison. Left to right: HV01, HV04, and HV06. 
  
Technical replicates from stimulated samples performed slightly more consistently than their 
unstimulated counterparts, with correlation coefficients between 0.809 and 0.951 (Figure 24). Again, 
this may indicate that cells exposed to a specific stimulus are pushed towards a more similar 
phenotype than unstimulated cells. Overall, agreement between technical replicates was good, 
although not perfect, and this can be explained by the use of patient-derived samples which display 
more inherent variability than cell lines. Furthermore, PBMCs are a heterogeneous cell population, 
comprising B and T lymphocytes, as well as monocytes/macrophages, and a small number of other 
immune cells such as dendritic cells. A substantial level of variation is therefore to be expected 
between patient samples. Finally, these technical replicates were PBMCs from the same individual 
plated in separate wells and incubated for a total of 48 h. Although these samples are considered 
technical replicates, more variation is generated than if cells from a single well were precipitated and 





Figure 24. Scatter plots showing correlation between protein groups identified in stimulated 
technical replicates 
log2 protein expression values from each experimental sample were plotted against those from other 
experimental samples. Numeric values at the top of each graph indicate the Pearson correlation 
coefficient for each comparison. Left to right: HV01, HV04, and HV06. 
 
Cellular component gene ontology (GO) analysis 
To confirm that the majority of proteins identified were in fact secreted proteins, we performed 
protein network and interaction analyses using the online database STRING. The 293 human proteins 
identified were added to STRING and mapped to the STRING database. The resulting network 
comprised 293 nodes and 3515 edges. The top four cellular component GO terms are shown in Table 
6. Top four cellular component GO terms and indicate that most proteins in the dataset were secreted 
or extracellular proteins, including vesicle-bound and exosomal proteins. This was confirmed using the 
GO enrichment tool FUNRICH, which mapped 76.9% of genes in the dataset to the GO term 
“exosomes” (p value = 7.08e-128). 
 











GO:0070062 Extracellular exosome 221 2.70e-130 
GO:0031988 Membrane-bound vesicle 228 1.01e-119 
GO:0044421 Extracellular region part 225 7.49e-110 
GO:0005576 Extracellular region 226 4.68e-95 
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Shared and unique protein groups identified 
We performed a presence/absence analysis on the data to investigate shared and unique protein 
groups identified. This analysis was done using data without imputed values, and a protein was 
considered ‘absent’ from a specific treatment condition if it had an LFQ intensity value of zero in all 
samples for that particular condition. Of the 293 human proteins identified, 233 were shared between 
control and Mtb-stimulated samples, while 40 were unique to control samples, and 20 were unique 
to Mtb-stimulated samples (Figure 25. Shared and unique proteins identified in control and Mtb-
stimulated samples. This indicates that 79.52% of the cells’ secretome remained qualitatively 








Figure 25. Shared and unique proteins identified in control and Mtb-stimulated samples 
 
We also compared shared and unique proteins identified in each biological replicate, per condition. In 
control samples, there were 161 proteins identified in all three biological replicates, and in Mtb-
stimulated samples, there were 166 proteins identified across biological replicates (Figure 26. Shared 
and unique proteins identified per biological replicate in control and Mtb-stimulated samples.). 
Therefore, 60.08% of proteins in control samples were identified in all replicates, compared to 67.76% 














Figure 26. Shared and unique proteins identified per biological replicate in control and Mtb-
stimulated samples. 
a. Control samples. b. Mtb-stimulated samples. 
 
Hierarchical clustering and principal component analysis 
We performed a hierarchical cluster analysis using a Euclidean model of absolute distance to 
determine whether samples in each group clustered together based on their protein expression 
profiles. These were visualized as heat maps, in which light blue bands indicate lower expression of 
the particular protein and darker bands indicate greater expression. Hierarchical clustering of the total 
proteome (Figure 27a) revealed strong clustering in each condition. However, since this analysis 
included both human and Mtb proteins, clustering was primarily driven by the presence and absence 
of Mtb proteins. The two orange boxes in Figure 27a highlight proteins whose expression is much 
greater in Mtb-stimulated samples and are therefore most likely Mtb proteins. Clustering analysis 
using only human proteins showed weak clustering, with one of the unstimulated sample from HV04 



























Figure 27. Hierarchical clustering analysis of protein expression profiles using log2 LFQ values 
a Human and Mtb protein expression. b human proteins only. 
 
A principal component analysis (PCA) was performed to further investigate clustering. When both 
human and Mtb proteins were included in the analysis, principal components 1 and 2, accounting for 
70.9 and 4.5% of the variation respectively, created distinct clusters, as shown in Figure 28. The 
presence and absence of Mtb proteins most likely accounts for much of this clustering, so PCA was 
repeated using human proteins only (Figure 28). Principal component 3 distinguished between control 













Figure 28. Principal component analysis of protein expression profiles (human and Mtb proteins) 
Red and pink dots represent control samples; blue and green dots represent Mtb-stimulated samples. 
Principal components 1 and 2 are represented on the x- and y-axis, respectively, and account for 70.9 














Figure 29. Principal component analysis of protein expression profiles (human proteins only) 
Blue dots represent control samples; red dots represent Mtb-stimulated samples. Principal 
components 1 and 3 are represented on the x- and y-axis, respectively, and account for 23.3 and 9.5% 
of the total variance, respectively. 
 
 
5.3.5 Preliminary biological analysis 
Differential expression analysis 
We performed paired Student’s t-tests to identify protein groups expressed differentially in the Mtb-
stimulated and control samples. Multiple testing correction (MTC) was applied following both the 
permutation-based and the Benjamini-Hochberg methods (FDR < 0.05). When the Benjamini-
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Hochberg MTC method was applied, the differences in proteins expressions between the Mtb-
stimulated and control samples were not considered statistically significant. However, use of the 
permutation-based method revealed differential expression of seven proteins shown in Figure 30 and 











Figure 30. Differentially expressed proteins in Mtb-stimulated samples 
Blue, up-regulated in Mtb-stimulated samples (FC > 2); orange, down-regulated in Mtb-stimulated 
samples (FC > 2); green, down-regulated in Mtb-stimulated samples (FC < 2). 
 









Q14697 GANAB Glucosidase II, 
alpha subunit 
Glycan metabolism, carbohydrate 
binding 
5.75e-4 -2.75 0.0067 




Cytoskeleton organization, Fc-γ 
receptor-mediated phagocytosis 
pathway, neutrophil degranulation 
0.003 -2.39 0.0400 
Q9NY33 DPP3 Dipeptidyl 
peptidase 3 
Peptide cleavage, zinc binding 0.002 -2.04 0.0300 




Mitochondrial DNA replication  0.003 -1.85 0.0460 
P08670 VIM Vimentin Maintains cytoskeletal integrity, 
involved in disassembly (apoptotic 
process) 
1.74e-4 -1.38 0.0080 
P63313 TMSB10 Thymosin β-10 Cytoskeleton organization 7.08e-4 +2.62 0.0150 











P62328 TMSB4X Thymosin β-4 Cytoskeleton organization, inhibits 
TNFα -induced NF-κB activation and 
IL-8 expression114 
0.002 +4.96 0.0288 
 
Thymosin β-4 (Tβ4) and β-10 (Tβ10) are both up-regulated in Mtb-stimulated samples (2.3-fold and 
1.4-fold, respectively).  Beta thymosins are small peptides expressed in multiple tissues, and show 
versatile intra- and extra-cellular activities. Tβ4 is implicated in motility and phagocytosis in 
macrophages, via sequestration of G-actin and regulation of actin polymerization.115 Furthermore, Tβ4 
has wound-healing, anti-inflammatory, and anti-microbial properties, and was shown to inhibit TNFα-
induced NF-κB activation and IL-8 expression.114 It is therefore an important immuno-regulatory 
protein. Tβ10 also sequesters actin monomers, and predisposes cells to undergo apoptosis.116 
Gutierrez-Pabello et al.116 showed that infection of bovine macrophages with Mycobacterium bovis 
induced over-expression of Tβ10 associated with macrophage apoptosis. It is therefore plausible that 
re-stimulation of human PBMCs with Mtb WCL would elicit a similar response and lead to over-
expression of Tβ10. 
 
Glucosidase II, also known as neutral alpha-glucosidase AB or alpha-glucosidase 2, is a key protein 
located in the endoplasmic reticulum (ER), and is involved in the quality control of glycoprotein folding. 
It was shown to increase in response to UV radiation, but is down-regulated in response to ER stress.117 
Lim et al. showed that Mtb infection caused an increase in ER stress, and demonstrated the association 
of ER stress-induced apoptosis with Mtb-induced cell death in murine macrophages.118 Apoptosis is 
an important host defence mechanism against intracellular pathogens such as Mtb, as it prevents the 
release of intracellular bacteria and components. Here, the down-regulation of glucosidase II, which 
is known to occur in response to ER stress, may be indicative of Mtb-induced ER stress in PBMCs. 
Although glucosidase II is an endoplasmic protein, it has previously been identified in the extracellular 
region (extracellular matrices and extracellular exosomes) as a secreted protein.119,120  
 
Actin-related protein 2/3 complex (Apr2/3) subunit 5 regulates actin polymerization and more 
specifically, the formation of the phagocytic cup (source: Reactome, R-HSA-2029482). ARPC5 has also 
been linked to Fcγ receptor-mediated phagocytosis and neutrophil degranulation (Reactome, R-HSA-
6798695). Neutrophil degranulation is a mechanism used to kill engulfed bacteria although there is 
controversy as to whether neutrophils are in fact able to kill Mtb once engulfed.121 ARPC5 is reportedly 
associated with cell migration and invasion in cancer,122 and finally, in the KEGG pathway database, it 





ARPC5 interacts with ARPC4, another Arp2/3 complex subunit, which itself binds to Mtb protein 
Rv1626, an essential secretory mycobacterial protein.123 According to Ghosh et al., this could be 
related to Mtb’s ability to alter the host cell cytoskeleton and use actin-based motility to infect new 
cells through direct cell-to-cell contact, by inducing actin polymerization through the recruitment of 
host cytoskeletal factors such as the Arp2/3 complex.123 
 
Dipeptidyl-peptidase III (DPP3) is an metallo-aminopeptidase which cleaves and degrades bioactive 
peptides and is involved in several physiological processes. Singh et al. investigated the negative 
correlation between DPP3 and IL-6 and showed that this cytokine is responsible for transcriptional 
down-regulation of DPP3, via the transcription factor CCAAT/enhancer binding protein beta (C/EBP-
b).124 Although IL-6 plays a complex role in Mtb infection, there is consensus about its up-regulation 
in response to macrophage infection by Mtb.125 It is therefore likely that re-stimulation with Mtb WCL 
induced increased IL-6 expression, which in turn caused down-regulation of DPP3.  
 
The last two proteins, vimentin and single-stranded DNA-binding protein (SSBP1), although 
significantly dysregulated, had changes in expression between one- and two-fold. It is common to 
exclude proteins with FC < 2 from further analysis, but I have included these here at there were only 
seven dysregulated proteins in total.  
 
Although single-stranded DNA-binding protein (SSBP1) is primarily a mitochondrial protein, it has 
previously been identified in B-cell derived extracellular exosomes.126 It is involved in mitochondrial 
DNA replication and repair, mitochondrial organization, and morphogenesis, and binds to ssDNA. It is 
unclear why this protein is significantly down-regulated in Mtb-stimulated PBMCs, but it may be 
related to Mtb-induced, reactive oxygen species (ROS)-mediated mitochondrial stress.127 
 
Vimentin is a type III intermediate filament that is responsible for maintaining cell integrity and shape. 
It is also associated with macrophage differentiation, phagocytosis, and production of ROS, is 
expressed on activated macrophages, and is secreted in response to pro-inflammatory signals.128 
Mahesh et al. showed that Mtb was able to down-regulate vimentin expression in macrophages. The 
authors suggest that expression of vimentin may be part of the inflammatory response of 
macrophages in an effort to contain the pathogens, and its down-regulation may be a result of Mtb’s 
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The aim of this experiment was to assess technical and biological variability, as well as confirm that 
we were able to isolate proteins from the PBMC secretome. The modified Bradford assay revealed 
very similar protein contents between biological and technical replicates. TIC chromatograms from 
technical replicated were also similar, with the exception of a few outliers. We investigated protein 
expression correlation through multi-scatter plots and assessed changes to the proteome in response 
to stimulation with Mtb WCL using Venn diagrams, heat maps, and PCA. Finally, we confirmed that 
proteins identified were primarily extracellular, thereby indicating that we had successfully isolated 
the cellular secretome. Preliminary biological analyses revealed that a small number of proteins were 
dysregulated in response to Mtb stimulation, consistent with the fact the PBMCs investigated here 
were derived from healthy volunteers and so were presumed to be naïve to Mtb antigens.  
 
This experiment confirmed that the sample processing methods used were appropriate and allowed 
for proteomic analysis of the cellular secretome. Biological and technical variability was low, and we 






Secretome analysis of PUFA-treated, healthy volunteer PBMCs 
 
6.1 Aim 
The aim of this experiment was to investigate the PBMC secretome and any changes associated with 
the re-stimulation of PBMCs with Mtb whole cell lysate (WCL). In addition, cells were pre-treated with 
n-3 PUFA (DHA and EPA, 100 nM each) or the vehicle control (2% ethanol) prior to re-stimulation with 
Mtb WCL to assess the effects of n-3 PUFA pre-treatment on cellular response to Mtb re-stimulation. 
PBMCs from four healthy volunteers were used. Cells were cultured as described in Chapter 4, and 
incubated for 24 h with Mtb WCL, in addition to 2-h pre-treatment with the vehicle control or n-3 
PUFA for the relevant treatment groups. 
 
6.2 Results and discussion 
6.2.1 Protein quantitation 
Total protein content in cell culture supernatants was quantified via modified Bradford assay. Mean 
total protein recovered from control samples was 1.90 µg, 4.37 µg for Mtb WCL only samples, 5.70 µg 
for Mtb WCL + vehicle samples, and 10.96 µg for Mtb WCL + PUFA samples (Figure 31). The differences 
in protein content between Mtb + PUFA samples and Mtb only samples were significant (p < 0.01), as 
were differences between Mtb + PUFA and Mtb + vehicle samples (p < 0.05). Differences in protein 
content between Mtb only and control samples (p < 0.05) may be partially accounted for by the 


















Figure 31. Total protein content in control, Mtb only, Mtb + vehicle and Mtb + PUFA samples 
Data are presented as means ± SD (error bars) of four biological replicates. *p < 0.05, ***p < 0.01. 
 
6.2.2 MS spectra, data quality, and protein identification 
MS spectra 
The supernatant samples were processed for MS-based proteomics (as per the method described I 
Chapter 3), and trypsin-digested peptides were subjected to discovery MS analysis on a Q Exactive 
instrument. The spectra obtained are shown in Figure 32, Figure 33, Figure 34, and Figure 35 below. 
These chromatograms display TICs from the four biological replicates (HV01, 02, 03, and 06) for each 
treatment condition. The four biological replicates performed consistently in most runs, as can be 
seen in the shape of the TIC. TIC variability is also shown in Figure 36, which reveals that TIC across 
Mtb only samples were much lower than that of other samples. Since TIC from the Mtb only samples 
were about half of that in the control samples (approximately 5e9 compared to approximately 10e9), 
comparison between the two treatment conditions would be hampered. Mtb + vehicle samples 
displayed the greatest scatter in TIC intensities and controls showed the least variability between 
samples.  
 
Peak retention times were very consistent across samples: for example, in Figure 32 (control), the 
same peak eluted at 53.16, 53.07, and 53.75 minutes for HV02, 03, and 06, respectively. Notable 
exceptions include the control sample for HV01 (Figure 32), which had a different TIC shape and lower 












































and much higher intensity. The maximum intensity for this sample was also higher than desired 
(2.26e10). Unfortunately, due to time constraints and the high demand for machine time, we were 
not able to rerun these samples to improve signal intensity. This sample was therefore excluded from 
further analyses. Chromatograms from three of the four Mtb only samples (Figure 33) revealed poor 
spray from approximately 68 to 80 min but again, due to time constraints, we were not able to repeat 
these runs. 
Figure 32. MS chromatogram (TIC) of control samples 
From top to bottom: black, HV01; red, HV02; green, HV03; blue, HV06. 
Figure 33. MS chromatogram (TIC) of Mtb only control samples 
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Figure 34. MS chromatogram (TIC) of Mtb + vehicle samples  
From top to bottom: black, HV01; red, HV02; green, HV03; blue, HV06. 
 
Figure 35. MS chromatogram (TIC) of Mtb + PUFA samples 











Figure 36. TIC variability across biological samples and treatment conditions 
E:\2016\...\Rerun\161114_Marine_rerun_1b 11/21/16 23:24:42
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The spectra generated via discovery MS analysis were submitted to MaxQuant for protein 
identification and quantitation. The number of spectra submitted was 607,484, of which 101,237 
(16.66 %) were identified. There were 13,323 peptides identified, mapping to 2083 protein groups. In 
order to improve the rate of spectra identified, we performed two alternative MaxQuant searches: 1) 
tryptic digestion was set to “semi-specific”, and 2) PSM FDR was set to 0.05. All other settings were 
kept the same (see Chapter 5). The results of these two alternative searches are shown in Table 8. 
Although more peptides and spectra were identified in the search with increased FDR, the number of 
protein groups identified was fractionally lower. Since increasing FDR to 0.05 may increase false 
positives and did not result in increased identifications, these settings were rejected. Similarly, the 
semi-tryptic search resulted in fewer peptides, protein groups, and spectra identified. Therefore, 
protein groups identified using the original search and standard settings were used for further 
analysis. The percentage spectra identified did increase compared to the initial optimization 
experiment described in Chapter 5, where only 12.63% spectra submitted were identified. This may 
be due to higher TIC intensities or better spray in the current experiment. 
 
Table 8. Summary of results obtained using standard and alternative MaxQuant search settings 
Settings Standard settings Semi-tryptic PSM FDR* = 0,05 
Protein groups 
identified 
2083 1652 2074 
Reverse hits 24 17 28 
% contaminants 4,66 4,60 4,29 
Peptides identified 13323 9548 13806 
Spectra submitted 607,484 606,287 607,345 
% spectra identified 16,66 13,52 20,53 
Modified peptides 845 623 831 
% no missed cleavages 61,8 61,4 62,4 
*Peptide-spectrum match false discovery rate 
 
Digestion efficiency 
Tryptic digestion efficiency was improved compared to that in the optimization experiment described 
in Chapter 5 by increasing the trypsin-to-sample ration to 1:10 (Figure 37). The percentage “no missed 










Figure 37. Tryptic digestion efficiency (missed cleavages) 
 
Distribution of LFQ intensities and correlation between biological replicates 
Protein groups were further analysed using the software Perseus. A total of 2083 protein groups were 
identified, of which 1559 were left after excluding proteins only identified by site, reverse hits, 
potential contaminants, and proteins identified with fewer than two unique peptides. Of these, 832 
were Mtb proteins and 727 were human proteins. Total protein LFQ intensities were then transformed 
by log2 and histograms were visualized to assess the distribution of the data (Figure 38). The data are 
primarily normally distributed, with some positive skewing (skewed to the right). LFQ intensity was 































Figure 38. Distribution histograms of log2-transformed protein LFQ intensities 
log2 protein LFQ were plotted to assess data distribution. Left to right: control, Mtb only, Mtb + 
vehicle, and Mtb + PUFA samples. Top to bottom: HV01, HV02, HV03, and HV06. Protein counts are 
lower in the control samples as these did not include any Mtb proteins. 
 
Scatter plots and Pearson’s correlation coefficients were generated for each set of biological replicates 
per condition. Overall, biological replicates performed similarly to one another, with Pearson’s 
correlation coefficients between 0.741 and 0.919. PUFA-treated samples were most strongly 

























Figure 39. Scatter plots showing correlation between protein groups identified in control, Mtb 
only, Mtb + vehicle, and Mtb + PUFA biological replicates 
log2 protein LFQ values from each experimental sample were plotted against those from other 
experimental samples. Numeric values at the top of each graph indicate the Pearson’s correlation 
coefficient for each comparison. a, controls; b, Mtb only samples; c, Mtb + vehicle; and d, Mtb + PUFA 
samples. The HV02 Mtb + vehicle sample was excluded from analysis due to poor LC-MS/MS 
performance. 
 
Hierarchical clustering  
Hierarchical clustering revealed strong clustering of samples per condition according to expression of 
both human and Mtb proteins, and expression of human proteins only (Figure 40). In Figure 40 (a), we 
see that the expression of certain proteins is down-regulated in Mtb only samples in comparison with 
the other three conditions (orange box 1). These proteins must be human proteins as they are strongly 







on human protein expression only (orange box 2). This indicates that re-stimulation with Mtb WCL 
causes decreased expression of certain proteins that are strongly expressed in control samples. 
 
“Control1” (HV01 control) is a clear outlier in Figure 40 (b) (human proteins) and appears to cluster 
more strongly with the Mtb only samples. This is supported by the slightly different TIC shape of this 
sample compared to that of the other three control samples (Figure 32). This difference may have 
arisen at the in vitro level (i.e., different cellular response to culture conditions) or in vivo (different 
immune status and response in the volunteer when blood was drawn). The fact that this sample seems 
to cluster closer to Mtb only samples could also indicate that this healthy volunteer, although 
asymptomatic at the time of blood collection, was mounting an immune response (perhaps to a cold 
or mild infection), or had experienced differential exposure to the Mtb pathogen (perhaps working in 
close contact with infected carriers). Finally, HV01 does not consume any alcohol whereas the other 
three volunteers reported regular alcohol consumption (see Chapter 3). This may be relevant as 
alcohol is a known immuno-modulatory agent.129 
 
Finally, there appears to be increased expression of certain proteins in the Mtb + PUFA samples, as 
shown by darker blue bands highlighted in orange box 3 in Figure 40 (b). These may be proteins whose 
expression is up-regulated in response to treatment with n-3 PUFA, as this increased expression is not 
seen in other conditions. N-3 PUFA-treated samples cluster separately from Mtb only samples on the 
one side, and control/vehicle control samples on the other, both of which are closely clustered, 




























Figure 40. Hierarchical clustering analysis of protein expression profiles using log2 LFQ values 
a Human and Mtb protein expression. b human proteins only. 
 
Principal component analysis 
A principal component analysis (PCA) was performed to further investigate clustering. The first PCA 
plot generated includes both human and Mtb proteins (Figure 41) while the second includes only 
human proteins (Figure 42. Principal component analysis of protein expression profiles (human 
proteins only). In Figure 41, principal component 1 clearly distinguished samples containing Mtb WCL 
from those that did not. In Figure 42, both components 1 and 2 created distinct clusters for each 
condition, with control samples (yellow) showing the most spread and variance (HV01 was already 











Figure 41. Principal component analysis of protein expression profiles (human and Mtb proteins) 
Yellow, control samples; blue, Mtb only samples; magenta, Mtb + vehicle samples; and green, Mtb + 
PUFA samples. Principal components 1 and 2 are represented on the x- and y-axis, respectively, and 
account for 66.3 and 12.1% of the total variance, respectively. 
 
 
Figure 42. Principal component analysis of protein expression profiles (human proteins only) 
Yellow, control samples; blue, Mtb only samples; magenta, Mtb + vehicle samples; and green, Mtb + 
PUFA samples. Principal components 1 and 2 are represented on the x- and y-axis, respectively, and 
account for 24.5 and 16.9% of the total variance, respectively. 
 
Cellular component GO analysis 
To confirm that we had successfully isolated the PBMC secretome, the 727 human proteins identified 
across all samples and conditions were added to STRING, thus creating a network of 713 nodes and 
12,464 edges. The top four enriched GO terms for cellular component revealed that approximately 












6.2.3 Biological analysis 
Shared and unique protein groups identified 
We performed a presence/absence analysis to investigate shared and unique protein groups amongst 
the identified protein groups. This analysis was done using data without imputed values, and a protein 
was considered ‘absent’ from a specific treatment condition if it had an LFQ intensity value of zero in 
all samples for that particular condition. It is important to note that this may not mean the protein is 
totally absent from the sample, but rather that it may be present but at a concentration that is below 
the level of quantification/detection of the mass spectrometer. Of the 585 quantifiable proteins 
identified, 240 (41.03%) were common to all four conditions (Figure 43). There were 56 proteins 
unique to the control samples, 5 to the Mtb only samples, 19 to the Mtb + vehicle samples, and 84 to 
the Mtb + PUFA samples. We performed GO enrichment analyses on the unique proteins identified in 









Figure 43. Shared and unique proteins identified in control, Mtb only, Mtb + vehicle, and Mtb + 
PUFA samples 




GO:0070062 Extracellular exosome 480 2.17e-260 
GO:0031988 Membrane-bound vesicle 494 1.57e-232 
GO:0044421 Extracellular region part 500 2.33e-194 
GO:0005576 Extracellular region 505 1.4e-83 
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The 56 proteins unique to control samples were uploaded to STRING and produced a network 
comprising 54 nodes and 115 edges (enrichment p-value: 1.25e-06, Figure 44). The top four enriched 
GO terms for biological process and molecular function are shown in Table 10 below. These terms are 
associated with ‘house-keeping’ and form part of the cell’s normal maintenance and function. 
Although there are several ribosomal proteins identified, all of these have previously been identified 
as exosomal proteins.126,130 Therefore, although they may be present in the cell culture supernatant 






















Table 10. Top four enriched GO terms for biological process and molecular function in proteins only 
quantifiable in control samples 






GO:0000184 nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay 
11 1.29e-10 
GO:0006401 RNA catabolic process 12 7.21e-10 
GO:0006614 SRP-dependent co-translational protein targeting to 
membrane 
10 7.21e-10 
GO:0019083 viral transcription 10 7.22e-10 
Molecular function 
GO:0003735 structural constituent of ribosome 8 4.35e-06 
GO:0044822 poly(A) RNA binding 17 4.35e-06 
GO:0003723 RNA binding 18 2.58e-05 
GO:0005198 structural molecule activity 9 1.26e-02 
 
The five proteins quantifiable only in Mtb only samples were also investigated in STRING. However, 
these proteins did not form a significantly enriched network. These are listed in Table 11 and include 
three notable proteins. Lipoprotein lipase, in addition to its role in lipoprotein hydrolysis, is known to 
positively regulate the inflammatory response and secretion of chemokines.131 Angiotensin-
converting enzyme (ACE) also plays a role in immunity through antigen processing and presentation 
via MHC class I and promoting mononuclear cell proliferation.132,133 Finally, apolipoprotein A-IV plays 
an anti-inflammatory role in the innate response134. These three proteins are therefore likely related 
to the immune response generated by re-stimulation of PBMCs with Mtb WCL. However, it is 
important to note that each of these five proteins was quantified in only one of four biological 
samples. Furthermore, these were not part of the proteins identified only in Mtb-stimulated samples 
in the previous experiment (Chapter 5). This disconnect between the two experiments may be related 











Table 11. Proteins quantified only in Mtb only samples 
Protein ID Gene Protein name Role 
P06858 LPL Lipoprotein lipase Hydrolysis of chylomicrons and very low-density 
lipoproteins (VLDL). Positive regulator of the 




Converts angiotensin I to II, inactivates bradykinin. 
Involved in antigen processing and presentation 
via MHC class I,133 mononuclear cell 
proliferation,132 and neutrophil-mediated 
immunity (inferred from homology) 
P06727 APOA4 Apolipoprotein A-IV Secretion and catabolism of chylomicrons and 
VLDL. Also involved in the innate immune 
response (anti-inflammatory)134 and removal of 
superoxide radicals135 
P35268 RPL22 60S ribosomal 
protein L22 
Heparin and RNA binding, structural constituent of 
the ribosome, translation 
O43488 AKR7A2 Aflatoxin B1 
aldehyde reductase 
member 2 
Catalyzes NADPH-dependent carbohydrate 
metabolic reduction reactions 
 
The 19 proteins uniquely quantified in vehicle control samples also did not form an enriched network 
in STRING. Notable proteins that play a role in the immune response are shown in Table 12. Notable 
proteins quantified only in Mtb + vehicle samples below. These include C-X-C motif chemokine 5, 
which plays a notable role in neutrophil activation and chemotaxis,136 thioredoxin domain-containing 
protein 17 and protein phosphatase 1A, both of which modulate TNF-α signaling and NF-κB 
activation,137,138 and finally complement C4-A, a complement component involved in propagation of 
the classical complement pathway.139 It is likely that these proteins were also present in other samples 
but may have been just below the level of quantification/detection. Furthermore, each of these 









Table 12. Notable proteins quantified only in Mtb + vehicle samples 
Protein ID Gene Protein name Role 
P42830 CXCL5 C-X-C motif 
chemokine 5 
Neutrophil activation,140 positive regulation of cell 
proliferation and neutrophil chemotaxis,136 
inflammatory response 




Disulfide reductase, modulates TNF-α signaling and 
NF-κB activation. Has peroxidase activity and may 
contribute to the elimination of cellular hydrogen 
peroxide137,141 
P35813 PPM1A Protein 
phosphatase 1A 
Plays an important role in the termination of TNF-α-
mediated NF-κB activation through 
dephosphorylating and inactivating IKBKB/IKKB,138 
negatively regulates TGF-β-mediated signalling142 
P0C0L4 C4A Complement C4-A Non-enzymatic component of C3 and C5 
convertases, essential for the propagation of the 
classical complement pathway. Covalently binds to 
immunoglobulins and immune complexes and 
enhances the solubilization of immune 
aggregates139 
 
The 84 proteins quantified only in Mtb + PUFA samples formed a STRING network comprising 80 nodes 
and 127 edges (enrichment p-value: 1.77e-07, Figure 45). These terms are associated with molecule 
assembly, metabolism, and RNA splicing/binding. Again, most of these proteins were quantified only 
in one of four biological samples, therefore it is unlikely that their presence in only treatment condition 





























Figure 45. STRING network of 84 proteins quantifiable only in Mtb + PUFA samples 
 
Table 13. Enriched GO terms for biological process and molecular function in proteins only 
quantifiable in Mtb + PUFA samples 






GO:0065003 macromolecular complex assembly 18 1.87e-03 
GO:0000398 mRNA splicing, via spliceosome 8 3.39e-03 
GO:0006461 protein complex assembly 15 3.39e-03 
GO:0044281 small molecule metabolic process 23 3.39e-03 
Molecular function 
GO:0003723 RNA binding 21 4.79e-04 




Comparison of control vs Mtb only samples 
We compared proteins quantified in control and Mtb only samples and visualized the intersection 
using a Venn diagram (Figure 46. Proteins quantified in control and Mtb only samples). This revealed 
that 254 out of 473 quantifiable proteins were common to both conditions (53.7%). However, there 
were 213 proteins quantifiable only in control samples, and six proteins uniquely quantifiable in Mtb 
only samples. This surprising result contradicts expectations that re-stimulation with Mtb WCL would 
induce increased protein expression in PBMCs, and instead suggests that re-stimulation may be down-









Figure 46. Proteins quantified in control and Mtb only samples 
 
We performed paired Student’s t-tests to identify protein groups expressed differentially in the four 
treatment conditions. Multiple testing correction (MTC) was applied following both the permutation-
based (PB) and the Benjamini-Hochberg (BH) methods (FDR < 0.05). When comparing control and Mtb 
only samples, only one protein was significantly dysregulated when applying PB MTC (Table 14). When 
applying BH MTC, no proteins were considered significantly differentially expressed, although 68 
proteins showed significantly different expression before any MTC was applied.  
 
Table 14. Differentially regulated protein in Mtb only samples (comparing to control) 
Protein 
ID 







family member 4 
Regulates lymphocyte survival and 





GTPase of immunity-associated proteins 4 (GIMAP4) is part of a family of septin-related guanine 
nucleotide-binding proteins that are abundantly expressed in immune cells. Knockout studies have 
shown the essential role of this protein family in the survival of lymphocytes, and interaction of 
GIMAP3, -4, and -7 with Bcl-2 proteins has suggested a role in the regulation of apoptosis.143  
 
It was anticipated that re-stimulation with Mtb WCL would produce a significant response in PBMCs, 
and it is therefore surprising that the expression of only one protein was significantly different when 
comparing the control with Mtb only group. The much lower TIC obtained in Mtb only samples 
compared to control samples may have masked more pronounced differences between these two 
treatment groups. Since a label-free quantitation approach is employed here, it is important for TIC to 
be matched across samples for accurate quantitation and comparison. 
 
We suggest that there may be several other reasons for which strong immune responses were not 
observed here. Ex vivo stimulation of immune cells with Mtb WCL has previously been shown to induce 
an immune response, such as an increase in IFN-γ production by NK cells,144 and production of nitric 
oxide in monocytes.145 The PBMCs re-stimulated in this experiment were derived from healthy donors 
who, to the best of our knowledge, were not infected with Mtb. Since the immune response is more 
pronounced after previous exposure to pathogens, this may explain why ‘Mtb-naïve’ cells from 
healthy donors responded less vigorously to challenge by Mtb WCL. Indeed, a much greater reaction 
was observed when this experiment was repeated in TB-infected patient-derived PBMCs (Chapter 7).  
 
It must also be noted that various concentrations of Mtb WCL have been used to re-stimulate immune 
cells in vivo. Here we have used 2 µg/mL, as in the work by Hoft et al.93 and von Reyn et al.,146 although 
higher concentrations of 10 µg/mL144,145,147 and 50 µg/mL148 have also been used. It is possible that a 
higher concentration of Mtb WCL would have elicited a greater response, but as a more prominent 
response was observed in patient-derived samples also stimulated with 2 µg/mL Mtb WCL, it is unlikely 
that the concentration used was too low. Another factor which may contribute here is the incubation 
time. Although most of the literature states 18-24 h incubation with the immunogenic stimulus, 
certain groups performed longer incubations such as 48 h (detection of NO production)145 or 72 h 
(detection of IFN-γ).147 Again, a slightly longer incubation period may have resulted in greater immune 
response. In our experiment, this had to be balanced by the risk of cell death increasing with prolonged 
culture in serum-free medium, which is why incubation could not be extended. 
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Further to this immunological reasoning, the data presented here may be skewed by mass 
spectrometry-related aspects, such as the “semirandom nature of data-dependent acquisition”.149 As 
previously mentioned, proteins not quantifiable in certain samples may be present at concentrations 
below the level of detection of the instrument in other samples. It is well-known that peptides 
experience different ionization efficiency, leading to observed enrichment of certain peptides over 
others in a manner that does not reflect biological significance. 
 
Mtb + vehicle samples vs Mtb only samples 
There were no significantly differentially regulated proteins identified when comparing vehicle 
controls with Mtb-stimulated samples. Although ethanol is known to have immune-modulatory 
effects, the concentration used in this experiment (0.2%) was too low to cause significant changes to 
the PBMC secretome.  
 
Mtb + PUFA samples vs Mtb + vehicle samples 
We compared proteins quantified in Mtb + vehicle and Mtb + PUFA samples to investigate the effects 
of n-3 PUFA treatment compared to that of the vehicle alone (Figure 46. Proteins quantified in control 
and Mtb only samples). This revealed that 353 of 666 quantifiable proteins were common to both 
conditions (53%). However, there were 183 proteins quantifiable only in Mtb + vehicle samples, and 
130 proteins uniquely quantifiable in Mtb + PUFA samples. This may indicate that treatment of PBMCs 
with n-3 PUFA prior to re-stimulation with Mtb WCL leads to expression of certain proteins (proteins 







Figure 47. Proteins quantified in Mtb + vehicle and Mtb + PUFA samples 
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Mtb + vehicle 
We investigated interactions between the 183 proteins quantified in Mtb + vehicle samples but not in 
Mtb + PUFA samples via STRING. The resulting network formed comprised 170 nodes and 567 edges 
with enriched GO terms for biological process, molecular function, and KEGG pathways listed in Table 
15. We hypothesize that since these proteins were not quantified in Mtb + PUFA samples, treatment 
with PUFA may have caused their down-regulation in Mtb-stimulated PBMCs. Since our study did not 
include a PUFA only control, without Mtb WCL, we are unable to conclude about the effects n-3 PUFA 
in isolation and can only observe the impact of n-3 PUFA treatment on Mtb-stimulated cells. 
Therefore, the ‘net effects’ include those of Mtb WCL re-stimulation and n-3 PUFA treatment. 
 
Table 15. Top four enriched GO terms for biological process, molecular function, and KEGG 
pathways in proteins quantified in Mtb + vehicle samples but not Mtb + PUFA samples 






GO:0006810 transport 68 2.57e-11 
GO:0051179 localization 74 4.62e-10 
GO:1903034 regulation of response to wounding 21 5.84e-09 
GO:0044765 single-organism transport 56 1.22e-08 
Molecular function 
GO:0005515 protein binding 78 9.67e-10 
GO:0004857 enzyme inhibitor activity 17 4.21e-06 
GO:0005539 glycosaminoglycan binding 13 7.52e-06 
GO:0030234 enzyme regulator activity 26 7.52e-06 
KEGG pathways 
03320 PPAR signalling pathway 8 1.34e-05 
04610 Complement and coagulation cascades 7 1.46e-04 
01100 Metabolic pathways 24 2.44e-03 
04510 Focal adhesion 9 2.87e-03 
 
Interestingly, the enriched GO terms for biological process seem to relate to the cell’s response to 
stimulus or stress. This is further supported by evidence from the enriched KEGG pathway term 
“complement and coagulation cascades”. The complement system mediates innate immunity and 
triggers the recruitment of inflammatory cells, as well as the opsonization and killing of pathogens. 
The coagulation cascade leads to the formation of thrombin, as well as a fibrin clot, and is closely 
related to the kinin-kallikrein system (KKS), which is itself involved in inflammation, coagulation, 
vascular permeability, and pain, amongst others.150 The interaction between these two pathways is 
shown in Figure 48. KEGG pathway for complement and coagulation cascade (04610) with red boxes 
indicating which proteins were identified in the current dataset. 
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Several complement proteins were identified here. Complement component 3 (C3, P01024), which 
plays a central role in the alternative and classical activation of the complement system and acts as a 
chemoattractant for neutrophils. Over-expression of C3 has been associated with metabolic disorders 
characterized by low-grade inflammation, such as insulin resistance, diabetes, and metabolic 
syndrome (MetS).151 Complement component 4A (C4A, P0C0L4), the product of C4 degradation, 
mediates local inflammation, and complement factor B (CFB, P00751), which is cleaved into two 
fragments and produces C3 convertase, is involved in the proliferation and differentiation of activated 
B lymphocytes. We also identified plasma protease C1 inhibitor (C1INH, P05155), which is involved in 
regulating complement activation, coagulation, fibrinolysis, and is an inhibitor of kallikrein. As a 
suppressor of inflammation, dysregulation of C1INH has been implicated in the pathogenesis of TB-
IRIS-associated chronic inflammation.152 Kininogen 1 (KNG1, P01042), a coagulation pathway 
component, was also identified. Hydrolysis of kininogens lead to formation of bradykinin, an 
important vasodilator and inflammatory mediator.150 Alpha-2-macroglobulin (A2M, P01023) is a 
regulator of complement activation via the lectin pathway, and ligand for IL-1153 and -8.154 Finally, 
antithrombin 3 (AT3, P01008) is an important protease inhibitor which inactivates several coagulation 



























Figure 48. KEGG pathway for complement and coagulation cascade (04610)  
Proteins highlighted in red boxes were identified in the current dataset. AT3, antithrombin 3; 
kininogen, KNG1; A2M, alpha-2-macroglobulin; C3, complement component 3; FB, complement factor 
B; C1INH, complement 1 inhibitor; C4a, complement component 4a. 
 
Since several key proteins relating to the complement and coagulation pathways were identified and 
quantified in Mtb + vehicle samples but not in samples pre-treated with n-3 PUFA, the data may 
suggest a decrease in complement and coagulation pathway involvement mediated by n-3 PUFA in 
Mtb WCL-stimulated PBMCs. With regards to literature investigating the effects of PUFA on the 
complement pathway, a recent study reported over-expression of C4 regulator miRNA after increased 
PUFA dietary intake, although this included both n-3 and n-6 PUFA.155 Phillips et al.151 investigated the 
interaction between PUFA and C3 polymorphisms in the context of MetS. This study revealed that n-
3 and n-6 PUFA led to both increased and decreased MetS risk, depending on the individual’s C3 gene 
variant, highlighting the difference in responses observed in individuals. The effects of n-3 PUFA on 
complement activation are not well understood, and performing targeted MS analysis on key 




Mtb + PUFA  
Interactions between proteins unique to Mtb + PUFA samples were further investigated through 
STRING. An enriched network comprising 125 nodes and 332 edges was produced and is shown in 
Figure 49. The top four GO terms enriched in biological process were macromolecular complex 
assembly, protein complex assembly, protein complex biogenesis, and mRNA splicing (Table 16). Since 
these terms are enriched in proteins expressed in Mtb + PUFA samples but not in Mtb + vehicle 
samples, we hypothesize that treatment with n-3 PUFA may cause increased expression of proteins 





















Figure 49. STRING network of 125 proteins quantified in Mtb + PUFA samples but not Mtb + vehicle 
samples 
Red nodes, proteins associated with the GO term “macromolecular complex assembly” (GO:0065003); 







Table 16. Top four enriched GO terms for biological process and molecular function in proteins 
quantified in Mtb + PUFA samples but not Mtb + vehicle samples 






GO:0065003 macromolecular complex assembly 28 7.4e-07 
GO:0006461 protein complex assembly 23 1.76e-05 
GO:0070271 protein complex biogenesis 23 1.76e-05 
GO:0000398 mRNA splicing, via spliceosome 11 0.000142 
Molecular function 
GO:0003723 RNA binding 31 3.01e-06 
GO:0044822 poly(A) RNA binding 26 6.34e-06 
GO:0003824 catalytic activity 54 0.00111 
GO:0005488 binding 85 0.00111 
 
Macromolecular assembly refers to the formation of structures such as organelles and membranes, 
comprising peptides, saccharides, and other macromolecules. This includes lipid rafts, which are 
plasma membrane micro-domains rich in cholesterol and sphingolipids that are not integrated into 
the membrane, but facilitate interactions between membrane lipids and proteins.156 N-3 PUFA are 
known to interact with and act upon cell membrane components such as lipid rafts. Fan et al.157 
investigated the effects on EPA and DHA on lipid raft constitution, demonstrating a significant 
decrease in sphingomyelin content in mouse-derived T cells. These sphingolipids play an important 
role in lipid raft formation and T cell activation. The stability of lipid rafts is disrupted by altering fatty 
acid composition and depleting sphingolipids, which may contribute to the decrease in T cell activation 
that is observed in response to n-3 PUFA treatment. Moreover, secretion of NF-κB and IL-2 is 
suppressed, as is the proliferation of lymphocytes as a result of n-3 PUFA interaction with lipid rafts. 
It was further shown that subsets of T cells (Th1 and Th2) respond differentially, and that n-3 PUFA 
may also inhibit antigen presentation via disruption of the lipid raft-dependent immunological 
synapse.156  
 
It is therefore likely that the terms macromolecular and protein complex assembly may relate to lipid 
rafts and modulation thereof. There were 11 proteins in this dataset that were previously identified 
as lipid raft-associated proteins by Chadwick et al.158 who isolated lipid rafts in the detergent-resistant 
membranes of mouse-derived brain tissue. However, to further investigate the effects of EPA and DHA 





“mRNA splicing” was another enriched GO term, which refers to the process by which introns are 
removed from mRNA molecules. Dietary changes are known to affect mRNA splicing, particularly that 
of glucose-6-phosphate dehydrogenase (G6PD). This enzyme catalyzes the first, rate-limiting step of 
the pentose phosphate pathway, which produces NADPH that is later used to synthesize fatty acids in 
the liver and adipose tissues.159 It was shown that an increase in dietary PUFA intake could inhibit 
splicing of G6DP mRNA and further, that enzymatic efficiency of mRNA processing for all lipogenic 
genes could be regulated by dietary PUFA.160 Another important enzyme that is regulated by 
alternative splicing is fatty acid desaturase 2 (FADS2). It is essential for the biosynthesis of n-3 and n-
6 PUFA, and alternative splicing is modulated by polypyrimidine tract binding protein 1 (PTBP1, 
UniProt ID P26599). Reardon et al.161 demonstrated that PTBP1 knock-down in HepG cells caused a 
significant decrease in n-3 PUFA relative to n-6 PUFA, especially with respect to the ratio of EPA to AA 
(43% decrease). PTPB1 was identified (with five unique peptides) and quantified only in Mtb + PUFA 
samples, suggesting a link between PUFA treatment and regulation of the expression and activity of 
PTBP1 in these samples. 
 
Identification of interleukins 
While we did identify several interesting and relevant proteins, there were no inflammation-specific 
proteins dysregulated. Of particular interest was the identification and differential quantification of 
cytokines (interleukins especially). Although no interleukins were significantly differentially regulated, 
it is worth noting that several were identified in this experiment.  
 
IL-8 (P10145, gene CXCL8) was identified with only one unique peptide, and was therefore excluded 
from further analysis. Interestingly, IL-8 was quantified in eight of 16 samples in this experiment, and 
in all conditions other than Mtb + PUFA samples. This chemotactic factor attracts other inflammatory 
mediators such as neutrophils, basophils, and T cells. It is involved in the activation of neutrophils and 
various other roles in the immune system. EPA and DHA have previously been reported to inhibit 
production of IL-8 induced by endotoxin in human endothelial cells,162 as well as in UVB-challenged 
keratinocytes,163 and endothelial progenitor cells.164 Our result therefore correlates well with this, but 





Pro-interleukin-16 (Q14005, gene IL-16) was identified with 18 unique peptides, in 15 of 16 samples. 
Finally, IL-19 (Q9UHD0, gene IL-19) was identified in only one sample (vehicle control) with two unique 
peptides. 
 
These low-abundance proteins are notoriously difficult to identify through LC-MS/MS-based methods 
so it is encouraging that we were at least able to identify three. A larger sample size and a targeted 
approach may reveal more in terms of the quantification and differential expression of such cytokines. 
 
6.4 Conclusion 
In this experiment, we aimed to assess the effects of re-stimulation with Mtb WCL in PBMCs isolated 
from four healthy volunteers, as well as investigate the effects of pre-treatment with n-3 PUFA. The 
secretome from these PBMCs was analyzed via MS-based proteomic methods, and the data were 
interrogated using statistical tests to reveal significant differences in protein expression between the 
various treatment groups. We were able to identify over 2000 proteins in total, of which 727 human 
proteins remained after filtering according to our set criteria.  
 
When comparing Mtb only and control samples, we identified one differentially regulated protein, 
which was not identified in our previous experiment (Chapter 5). This surprising result may be 
explained by our small sample size (n = 4 in this experiment, and n = 3 in the previous experiment). 
Furthermore, variation in this dataset is important as these are donor-derived samples. The greater 
the variation in protein expression, the more difficult it is to distinguish between biological variability 
and significant, treatment-induced differences in expression. By repeating this experiment and 
increasing the sample size, more meaningful conclusions may be drawn from the data.  
 
We also compared Mtb only samples with those pre-treated with n-3 PUFA. Although none of the 
proteins identified were considered significantly differentially regulated, qualitative analyses 
(presence/absence) revealed that several proteins from the complement and coagulation pathways 
quantified in Mtb + vehicle samples were not quantifiable in Mtb + PUFA samples. This may suggest 
down-regulation of these pathways by n-3 PUFA in Mtb WCL-stimulated PBMCs. In the current 
experiment, it may be difficult to tease out causal relationships as the effects of Mtb stimulation and 
n-3 PUFA treatment are compounded. The inclusion of a control treated with n-3 PUFA but not re-
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stimulated with Mtb WCL may have been of use to tease out the effects of both these perturbations. 
This is a limitation of the current study and should be considered in future work. 
 
While we saw a change in the PBMC secretome following pre-treatment with n-3 PUFA, it was not 
possible to conclude whether PUFAs exerted the anti-inflammatory effects that we expected, as we 
did not see a decrease in the expression of specific pro-inflammatory proteins. The addition of 
orthogonal biochemical methods such as ELISA or multiplex Luminex panels may contribute important 
data relating to the expression of lower abundance proteins, and particularly cytokines, chemokines, 
and growth factors (such as interleukins, TNF-α, IFN-γ, TGF-β, which are known pro-inflammatory 
mediators involved in TB immunity). Furthermore, it may be of interest to harvest cell culture 
supernatants at different time points, as different factors produced reach maximal concentration in 
cell medium at different times. Therefore, in the future, an experiment such as this one may be 
improved by i) increasing the sample size, ii) incorporating targeted MS-based proteomics and 
another, orthogonal method, iii) including different time points, and iv) including a control treated 








Secretome analysis of TB-IRIS patient-derived PBMCs: Part I 
 
7.1 Aim 
The aim of this experiment was to investigate the PBMC secretome of PBMCs derived from TB- and 
HIV-infected patients who developed TB-IRIS, and compare it to that of PBMCs from patients co-
infected with TB and HIV but who did not go on to develop TB-IRIS. As in Chapter 6, PBMCs were pre-
treated with n-3 PUFA and re-stimulated ex vivo with Mtb WCL, and the same methods for cell culture 
and sample processing for MS-based proteomics were applied. The current chapter presents and 
assesses patient characteristics, cell culture data, quality of MS chromatograms and protein 
identification, and sample clustering. 
 
7.2 Results and discussion 
7.2.1 Patient recruitment and characteristics 
The sub-study presented here is part of a larger study (TBTD2, HREC REF: 516/2011), and was 
approved by the University of Cape Town’s ethics committee (HREC REF: 136/2013). Patients were 
recruited from Ubuntu Clinic, Kayelitsha site B. As a densely populated and largely informal 
settlement, Kayelitsha hosts many previously disadvantaged, low-income communities. The incidence 
of HIV, TB, as well as DR-TB, is high,165 and many of the patients presenting at Ubuntu Clinic therefore 
require co-treatment. For this study, HIV/TB co-infected, ART-naïve but eligible patients were 
recruited and followed up for 12 weeks post ART initiation. The inclusion criteria were as follows: 
- Confirmed TB diagnosis (sputum smear positive, sputum culture positive, or clinical features 
highly suggestive of TB with diagnostic features on chest x-ray) 
- Confirmed HIV diagnosis  
- ART-naïve but eligible 






Exclusion criteria were as follows: 
- Patients younger than 18 years  
- Unknown or unconfirmed HIV status 
- TB infection not confirmed by smear microscopy and culture  
- Pregnancy 
- Current corticosteroid treatment 
 
As per national guidelines, patients began TB treatment immediately after confirmation of TB 
diagnosis, and ART was initiated within 2 weeks of TB treatment. Follow-up visits were conducted at 
2, 4, and 12 weeks post ART initiation. Extra visits were also scheduled in the event of clinical 
deterioration and appearance of symptoms suggestive of TB-IRIS. Data were collected from patients 
at various time-points and include patient history, description of symptoms, weight measurements, 
phlebotomy (weeks 2 and 4), urine sample collection, and clinical examination. 
  
Two patient groups were investigated in this study: the “non-IRIS” group (patients infected with TB 
and HIV who did NOT develop TB-IRIS), and the “IRIS” group (patients infected with TB and HIV who 
DID develop TB-IRIS). Blood samples used in this study are those collected two weeks after patients 
began ART, which is usually the time at which TB-IRIS symptoms first manifest.52 We thus expect to 
see the greatest differences between the proteome of IRIS patients and that of non-IRIS controls at 
this time point. As in the previous experiment, blood was drawn from patients and PBMCs were 
isolated within 4 h of blood collection by another student. Cells were then cryopreserved until further 
analysis. This sub-study comprised samples from 10 patients (n = 5 per group). Patient characteristics 
are listed in Table 17 below. There were six males and four females, aged 25 to 47 (mean = 34.8 years). 
Baseline CD4 counts varied quite widely from 4 to 233 cell/mm3, as did viral load (31,788 to 1,597,770 
copies/mL). The mean interval between the beginning of TB treatment and initiation of ART (TB-ART 
interval) was 18.3 ± 5.6 days. Recommendations have been made to begin ART immediately if CD4+ 
count < 50 cells/mm3, and to delay ART initiation until 8 weeks after starting TB treatment is CD4+ 
count > 50 cells/mm3 in order to limit toxicity and risk of developing TB-IRIS.56 Although six of the 
patients in this study had CD4+ counts < 50 cells/mm3 at baseline, ART was only initiated a minimum 


























CL1 non-IRIS 26 F 5 59,224 19 7 39.72 
CL2 non-IRIS 41 M 4 401,016 15 4.42 23.15 
CL3 IRIS 34 M 15 313,118 14 11.14 20.49 
CL4 IRIS 44 M 233 31,788 14 6.53 23.41 
CL5 non-IRIS 32 F 89 95,093 18 2.67 23.12 
CL6 non-IRIS?* 31 M 143 981,890 16 4.89 19.56 
CL7 non-IRIS 47 M 6 515,804 32 4.73 19.94 
CL8 IRIS 31 M 7 184,559 18 7.74 18.06 
CL9 IRIS?* 37 F 42 739,647 14 6.33 20.16 
CL10 IRIS 25 F 170 1,597,770 23 6.99 15.89 
Mean  34.80  71.40 491,990.90 18.30 6.24 22.66 
SD  7.36  83.46 496,212 5.60 2.30 6.87 
*Final classification is not available for patient CL6 and CL9. This is the current presumed classification. 
 
7.2.2 Cell recovery 
PBMCs were thawed, rested overnight, and cultured for a further 24 h after pre-treatment with n-3 
PUFA and re-stimulation with Mtb WCL. Cells were counted at the time of freezing, after the initial 
thaw, and after overnight rest. These results are presented in Figure 50. Number of cells recovered 
after thawing and overnight rest. The mean recovery ± SD was 35.72 ± 19.22% after thawing, and 
16.84 ± 12.27% following overnight rest. Thus, cell recovery from patient-derived samples was lower 
than that from healthy volunteer-derived PBMCs (Chapter 4, Figure 11) where percentage recovery 
after was thawing was 38.86%, and 36.97% after overnight rest. However, the difference in mean 
recovery after thaw was not significant (p > 0.05), and the difference in recovery after overnight rest 
was just significant (p = 0.05, Student’s t test, unpaired, two-tailed distribution). This suggests that 
PBMCs isolated from patients co-infected with Mtb and HIV may be less resistant to cryopreservation 
than their healthy counterparts; however, a larger sample size would be needed to confirm this. We 
also compared cell recovery rates between the two patient groups (TB-IRIS vs non-IRIS patients) and 
there were no significant differences in recovery after thaw or after overnight rest. Viability as 
assessed via Trypan blue exclusion assay was > 90% both directly after thawing and after overnight 
rest. However, cell recovery after overnight rest was < 10% for sample CL7. This sample was therefore 











Figure 50. Number of cells recovered after thawing and overnight rest 
Results are shown as mean cell numbers ± SD (error bars) from five TB-/HIV-infected patients with TB-
IRIS and five TB-/HIV-infected patients who did not develop TB-IRIS (controls). 
 
7.2.3 Protein quantitation 
Total protein was quantified via modified Bradford assay. In non-IRIS samples, mean total protein 
recovered from control samples was 0.43 µg, 0.97 µg for Mtb only samples, 1.91 µg for Mtb + vehicle 
samples, and 1.77 µg for Mtb + PUFA samples (Figure 31). These values for protein content follow the 
same trend as that seen in healthy donor cells. In IRIS samples however, mean total protein recovered 
from control samples was 2.19 µg, 3.81 µg for Mtb only samples, 1.53 µg for Mtb + vehicle samples, 
and 1.27 µg for Mtb + PUFA samples. This trend is different from that seen in both healthy volunteer 
cells and non-IRIS patient-derived cells. Since the inter-sample variation (SD, error bars in Figure 31) 
is important, the differences between protein content in non-IRIS and IRIS samples per condition were 
not significant, and neither were the differences between protein content between the different 
treatment conditions (p > 0.05). The differences seen here may result only from inter-sample 
variability, which is emphasized by the small sample size. A larger sample group would help to reduce 







































































Figure 51. Total protein content in control, Mtb only, Mtb + vehicle, and Mtb + PUFA samples 
Data are presented as means ± SD (error bars) with n = 4 for non-IRIS group samples and n = 5 for IRIS 
groups samples.  
 
7.2.4 MS spectra, data quality, and protein identification 
Samples were prepared in two batches with samples randomly assigned to each batch using Excel’s 
RAND function, and were submitted to LC-MS/MS analysis in an order that was generated randomly 
in order to minimize batch effects. 
 
MS spectra 
The spectra obtained by discovery MS analysis on a Q Exactive LC-MS/MS are shown in Figure 52 to 6 
(non-IRIS samples), and Figure 57 to 10 (IRIS samples) below. These display chromatograms from the 
biological replicates for each treatment condition (non-IRIS, n = 4; IRIS, n = 5). Overall, signal intensity 
was very low. Certain samples showed medium peptide peaks (with MS2) eluting at approximately 30 
min, but these were not present in all replicates/conditions. We hypothesize that these may be 
specific to certain patients, as the peak is present in certain patient samples only (for example, it is 
seen in CL5, in all treatment conditions), and may be related to particular patient characteristics. CL5 
has the lowest white cell count (WCC) of all patients (2.67x109/L at baseline), although the peak in 
question is also seen in CL3, which has one of the highest WCC (11.14x109/L). It is therefore more likely 
related to the fact that samples in which this peak appears have the lowest maximum intensity of all 















































control samples, the maximum intensity in CL5 is 5.81e9, which is the lowest of the four non-IRIS 
control replicates. This may suggest that increased signal intensity from the two greatest peaks seen 
in all samples (at 92.4 and 95.7 min) could be responsible for suppressing the peak at 30 min and 
would explain why it is only observed in samples with lower maximum signal intensity. The variation 
in TIC is shown in Figure 56 (non-IRIS samples) and Figure 61 (IRIS samples). TIC variation was relatively 
low for both sample groups. 
 
 
Figure 52. MS chromatogram (TIC) of non-IRIS, control samples  
Spectra from top to bottom: black, CL1; red, CL2; green, CL5; blue, CL6. 
 
Figure 53. MS chromatogram (TIC) of non-IRIS, Mtb only samples 
Spectra from top to bottom: black, CL1; red, CL2; green, CL5; blue, CL6. 
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Figure 54. MS chromatogram (TIC) of non-IRIS, Mtb + vehicle samples 
Spectra from top to bottom: black, CL1; red, CL2; green, CL5; blue, CL6. 
 
Figure 55. MS chromatogram (TIC) of non-IRIS, Mtb + PUFA samples 
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Figure 56. TIC variation in non-IRIS samples 
 
Figure 57. MS chromatogram (TIC) of IRIS, control samples 
Spectra from top to bottom: black, CL3; red, CL4; green, CL8; blue, CL9; yellow, CL10. 
 
Figure 58. MS chromatogram (TIC) of IRIS, Mtb only samples 
Spectra from top to bottom: black, CL3; red, CL4; green, CL8; blue, CL9; yellow, CL10. 
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Figure 59. MS chromatogram (TIC) of IRIS, Mtb + vehicle samples 
Spectra from top to bottom: black, CL3; red, CL4; green, CL8; blue, CL9; yellow, CL10. 
 
Figure 60. MS chromatogram (TIC) of IRIS, Mtb + PUFA samples 












Figure 61. TIC variation in IRIS samples 
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The two large peaks eluting at approximately 92.4 and 95.7 min in every sample are most likely 
contaminants (z = 1) originating from samples processing. We identified polyethylene glycol (PEG, 
415.21 Da) eluting at 92.4 min (Figure 62), as well as 44 Da transitions characteristic of PEG at 95.7 
min (Figure 63). Although the presence of such contaminants may suppress signal intensity from 
peptides, there does not appear to be any other peptides eluting at this time, as can be seen from the 
lack of MS2 spectra at 92 and 95 min (Figure 62). Furthermore, the intensity of these contaminant 
peaks is emphasized by comparing with the very low signal obtained from peptides in our samples. 
Unfortunately, due to the precious nature of clinical samples, we were not able to repeat this 










Figure 62. MS chromatogram (TIC) showing contaminant peaks at 92.4 min 









Figure 63. MS chromatogram (TIC) showing contaminant peaks at 95.7 min 





As per Chapter 6, ‘standard’ MaxQuant search settings were used. The number of spectra submitted 
to MaxQuant was 655,769, of which 35,215 (5.37 %) were identified. There were 6,569 peptides 
identified, mapping to 1306 protein groups. Summarized results are presented in Table 18 below. 
There were more spectra submitted in this experiment than in the previous experiment (655,769 vs 
607,484, Chapter 6). The number of peptides identified, however, was far lower (6,569 compared to 
13,323 in the previous experiment), as was the number of protein groups (1306 vs 2083 previously, 
Chapter 6). The most notable difference in protein identification results is undoubtedly the significant 
decrease in percentage spectra identified (5.37% here compared to 16.67% previously). This decrease 
is most likely multi-factorial. Since the TIC were low, many MS2 spectra may have had missing peaks 
which could not be assigned. Furthermore, clinical samples are, by nature, heterogeneous and 
complex. Since the samples in this experiment were obtained from patients co-infected with HIV and 
TB, the degree of complexity is likely to increase when compared to samples from healthy volunteers 
who are not infected with either HIV or TB.  
 
Table 18. Summary of results obtained from the peptide/protein identification search using 
MaxQuant standard settings. 
Parameter Result 
Protein groups identified 1306 
Protein groups identified with 
>2 unique peptides 
937 
Reverse hits 12 
% contaminants 3.29 
Peptides identified 6,569 
Spectra submitted 655,769 
% spectra identified 5.37 
Modified peptides 400 
% no missed cleavages 61,9 
 
MaxQuant was unable to process samples CL5D (CL5, Mtb + PUFA) and CL6C (CL6, Mtb + vehicle), as 




Tryptic digestion efficiency was satisfactory (61.9% no missed cleavages) and highly comparable to the 












Figure 64. Tryptic digestion efficiency (missed cleavages) 
 
Distribution of LFQ intensities and correlation between biological replicates 
Protein groups were loaded to Perseus for further analysis. A total of 1306 protein groups were 
identified, of which 908 were left after excluding proteins only identified by site, reverse hits, potential 
contaminants, and proteins identified with fewer than two unique peptides. Of these, 230 were Mtb 
proteins and 678 were human proteins. Total LFQ values were then transformed by log2 and the 
distribution of the data was visualized through histograms (Figure 65). This data shows positive 
skewing to the right, and although we imputed missing values from the normal distribution, this 
indicates that this method may not be the most appropriate approach. To circumvent this problem, 
we focused primarily on qualitative analyses (presence/absence of proteins) to derive biological 



































Figure 65. Distribution histograms of log2-transformed protein intensities 
log2 LFQ values were plotted to assess data distribution. Left to right: control, Mtb only, Mtb + vehicle, 
and Mtb + PUFA samples. Top to bottom: CL1 to CL10 (CL6C and CL5D are excluded). Protein counts 
are lower in the control samples as these did not include any Mtb proteins.  
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Scatter plots and R2 values (Pearson correlation) were generated for each set of biological replicates 
per condition. The correlation between samples from the non-IRIS groups for each treatment 
condition is shown in Figure 66 and that of samples from the IRIS group in shown in Figure 67. Overall, 
the correlation between biological replicates was not as strong as that between healthy volunteer 
replicates. In the non-IRIS group, control samples were most poorly correlated (Pearson correlation 
between 0.281 and 0.769, Figure 66) and Mtb + PUFA samples were most closely correlated (Pearson 
correlation between 0.584 and 0.702). The same trend was observed in the IRIS group (Figure 67) 
where Pearson correlation values for controls were between 0.129 and 0.700, and between 0.311 and 
0.739 for n-3 PUFA-treated samples.  
 
Poor correlation between biological replicates is most likely due to increased sample complexity, 
contributed by the patients’ co-infection with HIV and TB. Furthermore, as can be seen in Table 17, 
patient characteristics related to disease and the immune system varied vastly (CD4+ count, viral load, 
and WCC). This suggests that PBMCs isolated from these patients may have very different responses 
to cryopreservation, in vitro culture, treatment with n-3 PUFA, and re-stimulation with Mtb WCL. 
These biological differences, which create ‘noise’, would be much less prominent if the sample size 
was greater. Repeating this experiment with a greater number of samples would therefore be 





























Figure 66. Scatter plots showing correlation between abundance of protein groups identified in 
control, Mtb only, Mtb + vehicle, and Mtb + PUFA biological replicates from the non-IRIS group 
log2 LFQ values from each experimental sample were plotted against those from other experimental 
samples. Numeric values at the top of each graph indicate the Pearson correlation value for each 

































Figure 67. Scatter plots showing correlation between abundance of protein groups identified in 
control, Mtb only, Mtb + vehicle, and Mtb + PUFA biological replicates from the IRIS group 
log2 LFQ values from each experimental sample were plotted against those from other experimental 
samples. Numeric values at the top of each graph indicate the Pearson correlation value for each 










Hierarchical clustering  
Hierarchical clustering revealed weak clustering of samples by treatment condition, in both the non-
IRIS and IRIS group samples (Figure 68). In the non-IRIS group (Figure 68 a), control samples (A) 
clustered together (right, labelled CL1 to CL6A). However, samples from the other three conditions 
did not cluster separately from each other. The proteins highlighted in orange box 1 seem to be over-
expressed in all conditions re-stimulated with Mtb WCL, but not in control samples. These proteins 
may therefore be specific to the cells’ response to Mtb challenge. Orange box 2 highlights proteins 
over-expressed specifically in samples Mtb only (B), Mtb + vehicle (C), and Mtb + PUFA samples (D) 
from CL1 and CL2. In addition, these four samples clustered separately from all others. It was observed 
that CL1 and CL2 had the lowest baseline CD4+ cell counts with 5 and 4 cells/mm3, respectively, 
whereas the mean was 71.4 cell/mm3. This low CD4+ cell count may affect the cellular response to ex 
vivo re-stimulation with Mtb WCL and lead to the slightly different protein expression pattern 
observed here. Furthermore, orange box 3 shows increased protein expression unique to samples 
CL1B and CL2D. 
 
In the IRIS group (Figure 68 a), controls (A) also clustered together on the right, with the exception of 
CL10. Surprisingly, sample CL4C (Mtb + vehicle) also clustered with the controls. Orange box 4 defines 
protein expression that in increased in all samples re-stimulated with Mtb WCL, and box 5 highlights 
over-expression specific to certain samples (Mtb only, Mtb + vehicle, and Mtb + PUFA). These 
differential responses may be sample-specific and patient-related, as there is no indication in the 



























Figure 68. Hierarchical clustering analysis of human protein expression profiles for non-IRIS and 
IRIS group samples, using log2 LFQ values 
a. Non-IRIS group, b. IRIS group. Treatment condition codes: A, control; B, Mtb only; C, Mtb + vehicle; 
D, Mtb + PUFA. 
 
Principal component analysis 
A principal component analysis (PCA) was performed to further investigate clustering. In non-IRIS 
samples (Figure 69), control samples (yellow) clustered together and away from all other samples re-
stimulated with Mtb (ellipse 1). This is consistent with a predominantly coordinated response to Mtb 
antigens, as is expected from non-IRIS patient-derived PBMCs. There was no obvious clustering 
observed in samples from the other three conditions, even when principal components other than 









more closely thus creating three subsets: CL1C and CL1D (ellipse 2); CL2B, CL2C, CL2D, and CL1C 









Figure 69. Principal component analysis of protein expression profiles for non-IRIS group samples 
Yellow, control samples; blue, Mtb only samples; magenta, Mtb + vehicle samples; and green, Mtb + 
PUFA samples. Principal components 1 and 2 are represented on the x- and y-axis, respectively, and 
account for 42.1 and 19.6% of the total variance, respectively. 
 
Clustering was far less defined in the IRIS group (Figure 70). Four of the five controls clustered together 
with the exception of CL10. CL9B, CL9C, CL4C, and CL10C also clustered with the control samples 
(ellipse 1). There was no clear clustering in the other samples, suggesting a high degree of patient-
related variability in cellular response to re-stimulation with Mtb WCL and treatment with the vehicle 
or n-3 PUFA. We also investigated plots obtained when comparing other principal components, but 
clustering did not improve. This is consistent with previous proteomic data that suggests that PBMCs 

























Figure 70. Principal component analysis of protein expression profiles for IRIS groups samples 
Yellow, control samples; blue, Mtb only samples; magenta, Mtb + vehicle samples; and green, Mtb + 
PUFA samples. Principal components 1 and 2 are represented on the x- and y-axis, respectively, and 
account for 31.8 and 18.5% of the total variance, respectively. 
 
Finally, we compared all samples across both the non-IRIS and IRIS groups to assess whether samples 
from these two patient groups clustered separately (Figure 71), but found that these two groups of 
samples did not cluster away from each other. This is most likely due to the inherent biological 









Figure 71. Principal component analysis of protein expression profiles for both non-IRIS and IRIS 
groups samples 
Green, non-IRIS group samples; red, IRIS group samples. Principal components 1 and 2 are represented 




Cellular component GO analysis 
To confirm that we had successfully isolated the PBMC secretome, the 678 human proteins identified 
across all samples and conditions were added to STRING, thus creating a network of 678 nodes and 
10,008 edges. The top four enriched GO terms for cellular component revealed that approximately 
67% of proteins identified were extracellular (Table 9), with very small false discovery rates. 
 






The current chapter aimed to present and assess patient characteristics, cell culture data, quality of 
MS chromatograms and protein identification, and sample clustering. Protein identifications were 
lower than those of the previous experiment involving healthy volunteer cells (Chapter 6), as was the 
percentage of spectra identified. We expect that protein quantitation via Bradford assay may be 
resulting in over-estimation of the protein concentration, with downstream effects on data generated 
via MS analysis. Going forward in future experiments, use of a more sensitive protein quantitation 
method should be considered. Similarly, correlation of protein identification between the biological 
replicates was weaker than that observed in the previous experiment. Furthermore, PCA and 
hierarchical clustering was also weak. This may be due to the fact that the samples are derived from 
TB/HIV-infected individuals, who may present significant differences in their response to the disease 
as well as disease status and progression. Because of the high degree of variability in this dataset, and 
the non-normal distribution of protein expression, biological analyses must rely primarily on 
qualitative observations such as the presence and absence of proteins from certain datasets. This is 
further explored in Chapter 8.  
  




GO:0070062 extracellular exosome 438 1.35e-223 
GO:0031988 membrane-bounded vesicle 452 1.7e-199 
GO:0031982 vesicle 453 7.21e-195 




Secretome analysis of TB-IRIS patient-derived PBMCs: Part II 
 
8.1 Aim 
This chapter follows on from Chapter 7, with the aim of investigating the PBMC secretome of PBMCs 
derived from TB- and HIV-infected patients who developed TB-IRIS, and compare it to that of PBMCs 
from patients co-infected with Mtb and HIV but who did not go on to develop TB-IRIS. The current 
chapter investigates the biological significance of the data generated in Chapter 7. 
 
8.2 Biological results 
8.2.1 Shared and unique protein groups identified 
We performed a presence/absence analysis on the data to investigate shared and unique protein 
groups identified. This analysis was done using data without imputed values, and a protein was 
considered ‘absent’ from a specific treatment condition if it had an LFQ intensity value of zero in all 
samples for that particular condition. Of the 488 quantifiable proteins identified in the non-IRIS group, 
83 (17%) were common to all four conditions (Figure 72). There were 23 proteins unique to the Mtb 
only samples, 25 to the Mtb + vehicle controls, and 35 to the Mtb + PUFA samples. Interestingly, there 
were 235 proteins (48.2%) common to the Mtb only, Mtb + vehicle, and Mtb + PUFA sample groups, 
and this is consistent with the PCA plots in Chapter 7. This suggests that these proteins may be part of 
the response to re-stimulation with Mtb WCL as these three sample groups were cultured with Mtb 
WCL whereas the controls were not. This therefore confirms that re-stimulation with Mtb WCL elicited 
the expected immune response. From this analysis, we can tell that controls from this non-IRIS group 
had markedly different protein expression profiles that Mtb only, Mtb + vehicle, and Mtb + PUFA 
samples. This trend was not observed in healthy donor PBMCs and may therefore be specific to PBMCs 











Figure 72. Shared and unique proteins identified in control, Mtb only, Mtb + vehicle, and Mtb + 
PUFA samples in the non-IRIS group 
 
In the IRIS group, 657 proteins identified were quantifiable, of which 289 (43.9%) were common to all 
conditions (Figure 73. Shared and unique proteins identified in control, Mtb only, Mtb + vehicle, and 
Mtb + PUFA samples in the IRIS group). There were two proteins unique to the controls, 15 to the Mtb 
only samples, 29 to Mtb + vehicle, and 103 to Mtb + PUFA samples. In this group, most proteins were 










Figure 73. Shared and unique proteins identified in control, Mtb only, Mtb + vehicle, and Mtb + 
PUFA samples in the IRIS group 
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8.2.2 Comparing non-IRIS and IRIS sample groups 
Controls 
We also investigated proteins quantifiable in each condition and compared those identified in the 
non-IRIS group with those of the IRIS group. With regards to controls, a total of 330 proteins were 
quantifiable, of which 245 were quantified only in the samples from the IRIS group, and 1 in samples 
from the non-IRIS group (Figure 74). This important difference in proteins identified suggests that 
PBMCs from patients with IRIS secrete more proteins than their counterparts from non-IRIS patients. 
This is to be expected, since patients with TB-IRIS experience increased inflammation even at baseline, 
and thus produce more proteins as part of the immune response.  
 
To further investigate this, we loaded the list of 245 proteins quantifiable only in IRIS samples to 
STRING. A network comprising 238 nodes and 1,197 edges was produced. The top four enriched GO 
terms for biological process and listed in Table 20. These terms relate to the negative regulation of 
apoptosis, as well as the immune response and response to stress. These results therefore suggest the 
increased activation of the immune system and stress response in PBMCs from the IRIS group, even 
at baseline (i.e., before re-stimulation with Mtb WCL or other treatment), rather than an increase in 
cell death. Most notably, IL-1β was quantified only in IRIS samples. This potent pro-inflammatory 
cytokine has been linked to aberrant inflammation in TB-IRIS before,50 and it is interesting to see that 
it was not quantified in the non-IRIS group, suggesting that IL-1β was probably present in the non-IRIS 
group but at a level below the limit of detection/quantitation of the instrument. This result correlates 
well with the study conducted by Tadokera et al.,50 which investigated cytokine levels in PBMC culture 
supernatants using Luminex. Levels of IL-1β were significantly greater in samples from IRIS patients (p 











Figure 74. Proteins quantifiable in control samples from the non-IRIS and IRIS groups 
 
Table 20. Top four enriched GO terms for biological process in proteins only quantifiable in control 
samples from the IRIS group 
GO pathway ID Description Gene 
count 
False discovery 
rate GO:0043066 negative regulation of apoptotic process 42 8.34e-14 
GO:0060548 negative regulation of cell death 43 1.33e-13 
GO:0002684 positive regulation of immune system process 38 1.6e-11 
GO:0006950 response to stress 82 1.6e-11 
 
Next, we performed a PCA using only control samples from both the non-IRIS and IRIS groups (Figure 
75). The two groups clustered separately from one another, suggesting differences in PBMC status at 
baseline, as these samples were not yet perturbed with any stimulus. It must be noted that this may 
be partially driven by the fact that 245 out 350 proteins were quantified only in IRIS group samples. 
However, this result also correlates with the literature and findings that several markers appear to be 
dysregulated at baseline and two weeks after ART initiation in patients who go on to develop TB-IRIS. 
This includes differences in the number and distribution of killer immunoglobulin receptors,167 
increased plasma IL-6, IL-12, CRP, IL-18, IL-1β, TNF-α, and IL-8 levels,43,50,168 increased CSF cytokine, 
chemokine, and MMP levels,169 increased and imbalanced C1q and C1-INH levels,152 increased NK cell 
degranulation capacity,170 and increased TLR2 levels.171 Therefore, the differences in protein 
expression observed here between the non-IRIS and IRIS groups may result from such changes. The 
outlier to the right, CL10, has the highest viral load (1,597,770 copies/mL, mean = 491,990.90 
copies/mL) and the lowest BMI (15.89, mean = 22.66). These factors may contribute to the different 
protein expression profile observed here. 
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Figure 75. Principal component analysis of protein expression profiles for control samples from 
both the non-IRIS and IRIS groups  
Green, non-IRIS group samples; red, IRIS groups samples. 
 
Finally, we performed Student’s t-tests to identify differential protein expression amongst the 84 
proteins shared between the non-IRIS and IRIS groups, but no proteins were considered significantly 
differentially expressed. 
 
Mtb only samples 
The same comparison was made for Mtb only samples. Of the 472 proteins quantified, 375 were 
common to both groups (Figure 76). There were 45 proteins unique to non-IRIS, but there was no 
enriched network formed when this list was loaded to STRING. The 52 proteins unique to the IRIS 
group formed a network comprising 52 nodes and 69 edges with two enriched GO terms for biological 
process, although the false discovery rates were relatively high for these terms (Table 21). The term 
“viral process” is particularly relevant here, as these samples were obtained from HIV-positive 
patients. In addition, two pro-inflammatory mediators and key players in the immune response were 










Figure 76. Proteins quantifiable in Mtb only samples from the non-IRIS and IRIS groups 
 
Table 21. Top four enriched GO terms for biological process in proteins only quantifiable in Mtb 
only samples from the IRIS group 




rate GO:0044403 symbiosis, encompassing mutualism through parasitism 11 1.65e-2
GO:0016032 viral process 10 2.53e-2 
 
IL-16 is an important cytokine known to promote migration of CD4+ lymphocytes, monocytes, and 
eosinophils, as well as stimulate IL-2 receptor and HLA-DR4 expression in T cells. In addition, it 
enhances CD4+ T cell responses to IL-2 and IL-15, and can suppress HIV transcription. Since PBMCs 
were isolated from HIV-positive patients, it is not unexpected to see IL-16. However, identification of 
IL-16 only in IRIS samples suggests that it is present at a higher level than in non-IRIS samples where 
levels may fall below the limit of detection/quantitation.  
 
IL-6 is another cytokine that was quantifiable only in Mtb only samples from the IRIS group. Similarly 
to IL-1β, secretion of IL-6 was shown to be up-regulated in cell culture supernatants (p < 0.0001, n = 
20 non-IRIS controls and 19 IRIS patients) and in TB-IRIS patient sera (p = 0.0002, n = 20 non-IRIS 
controls and 20 IRIS patients).50 Furthermore, in the same study, Tadokera et al.50 investigated the 
induction of genes in patient-derived PBMCs cultured in the presence/absence of heat-killed Mtb 
H37Rv after 6 and 24 h. At the 6-h time-point, IL-6 was induced >100-fold in Mtb-stimulated samples, 
and induction was greater in IRIS patient samples, with p-value < 0.05 after Bonferroni multiple testing 
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correction (MTC). Similar results were obtained at the 24 h time-point. Our proteomic results 
therefore correlate well with the gene expression work done by Tadokera et al. 
 
Table 22. Key pro-inflammatory proteins quantified only in Mtb only samples from the IRIS group 
Protein ID Gene Protein name Role 
Q14005 IL-16 Interleukin 16 stimulates a migratory response in leucocytes, 
induces IL-2 receptor expression in T cells 
P05231 IL-6 Interleukin 6 induces acute phase response, response to gram-
negative/-positive bacteria 
 
We also performed a PCA to investigate clustering of non-IRIS and IRIS samples re-stimulated with 
Mtb WCL (Figure 77). There was no clear clustering observed, and IRIS group samples seem to be more 
variably distributed across the plot, whereas non-IRIS samples formed two distinct groupings. Other 
principal components were investigated but did not lead to more distinct clustering. 
Figure 77. Principal component analysis of protein expression profiles for Mtb only samples from 
both the non-IRIS and IRIS groups 
Green, non-IRIS groups samples; red, IRIS group samples. 
 




Mtb + vehicle samples 
When comparing vehicle control samples from the non-IRIS and IRIS group, we found 546 quantifiable 
proteins, 337 of which were common to both groups (Figure 78). Again, there were more proteins 
unique to the IRIS group than the non-IRIS group (162 vs 47, respectively). The 47 proteins unique to 
non-IRIS samples formed an enriched network with 35 edges in STRING. The top four enriched GO 
terms for biological process indicate the effect of the vehicle (0.2% ethanol) on processes such as fatty 
acid β oxidation, and regulation of homeostasis particularly with regards to body fluids. Ethanol is 
known to have an inhibitory effect on fatty acid oxidation and stimulate hepatic fatty acid 
synthesis.172,173 
 
The 162 proteins quantified only in IRIS vehicle controls formed a STRING network with 641 edges, 
with the following enriched GO terms for biological process: mRNA metabolic process (GO:0016071), 
RNA splicing (GO:0008380), and mRNA processing (GO:0006397). It is unclear why these terms are 
enriched in the set of proteins quantified only in IRIS samples as these are considered part of the cell’s 







Figure 78. Proteins quantifiable in Mtb + vehicle samples from the non-IRIS and IRIS groups 
 













Figure 79. Principal component analysis of protein expression profiles for Mtb + vehicle samples 
from both the non-IRIS and IRIS groups 
Green, non-IRIS groups samples; red, IRIS groups samples. 
 
After performing Student’s t-tests, we found no proteins significantly differentially expressed. 
 
Mtb + PUFA samples 
Of the 606 quantifiable proteins identified in Mtb + PUFA samples, 398 were common to the non-IRIS 
and IRIS groups. The nine proteins unique to the non-IRIS group did not form an enriched STRING 
network. Interestingly, IL-1α (present at 0.537 ppm) was quantified in non-IRIS samples. This cytokine 
is produced by activated macrophages and is associated with the inflammatory response. We 
uploaded the 199 proteins quantified uniquely in samples from the IRIS group, and produced a 
network with 911 edges. As in vehicle controls, the top four enriched GO terms for biological process 







Figure 80. Proteins quantifiable in Mtb + PUFA samples from the non-IRIS and IRIS groups 
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Finally, the PCA did not reveal any clustering of non-IRIS and IRIS groups samples, as can be seen in 
Figure 81. 
Figure 81. Principal component analysis of protein expression profiles for Mtb + PUFA samples 
from both the non-IRIS and IRIS groups 
Green, non-IRIS group samples; red, IRIS groups samples. 
 
Finally, as with other treatment conditions, no proteins were found to be significantly differentially 
expressed here, after MTC. 
 
8.2.3 Comparing treatment conditions 
Controls vs Mtb only samples  
To investigate the effects of re-stimulating patient-derived PBMCs with Mtb WCL, we compared the 
proteins identified in control and Mtb only samples, for each patient group. A Venn diagram showing 
the overlap of proteins identified in control an Mtb only samples from the non-IRIS group is shown in 
Figure 82 below. There were 336 proteins quantifiable only in Mtb only samples, suggesting that re-
stimulation with Mtb WCL may be promoting increased expression of proteins as part of the immune 










Figure 82. Proteins identified in control and Mtb only samples from the non-IRIS group 
 
The 84 (19.95%) proteins common to both conditions comprised 15 histone proteins and were 
associated with histone H4-K20 demethylation (GO:0035574) and RNA binding (GO:0003723). The 
presence of histone proteins may indicate cell death occurring during culture, but as these proteins 
were common to both control and Mtb only samples, it is likely that this is regular cell death associated 
with in vitro culturing rather than directly related to re-stimulation with Mtb WCL. 
 
The 336 proteins unique to Mtb only samples were associated with the four GO terms listed in Table 
23. These terms confirmed the activation of the immune response by in vitro re-stimulation, and this 
was further supported by enriched KEGG pathways also listed in Table 23. IL-1α and IL-1β were also 










Table 23. Enriched GO terms for biological process and KEGG pathways in proteins only 
quantifiable in Mtb only samples from the non-IRIS group 
GO pathway ID Description Gene 
count 
False discovery 
rate Biological process 
GO:0006950 response to stress 121 2.8e-18 
GO:0002684 positive regulation of immune system process 55 3.32e-17 
GO:0065008 regulation of biological quality 109 3.92e-17 
GO:0002376 immune system process 84 6.72e-16 
KEGG pathways 
05130 Pathogenic Escherichia coli infection 11 5.22e-08 
05100 Bacterial invasion of epithelial cells 12 1.11e-07 
 
We performed Student’s t tests to compare protein expression in control and Mtb only samples from 
the non-IRIS group. When Benjamini-Hochberg multiple testing correction (MTC) was applied, no 
proteins were considered significantly differentially expressed, but when the permutation-based FDR 
MTC method was used, the expression of two proteins was considered significantly different (Table 
24). 
 




Gene Protein name Role P-value Fold-
change* 
P07237 P4HB Protein 
disulfide-
isomerase 
redox homeostasis, response to oxidative 
stress, IL-12 signaling pathway174 
2.64e-4 -3.52 
Q9UI08 EVL Ena/VASP-like 
protein 
cytoskeletal remodeling, cell migration175 5.09e-4 +1.49 
*Direction of fold-change: Mtb only/control samples. 
 
When the same comparison is made with samples from the IRIS group, we notice that many more 
proteins are common to both conditions (300 proteins, 57%, Figure 83). We hypothesize that this may 
be caused by the overly active immune response seen in IRIS patients, even before re-stimulation. To 
validate this hypothesis, we further investigated the 300 proteins common to both conditions and the 
proteins unique to each condition in STRING. The GO terms most enriched in proteins common to 
both conditions are listed in Table 25  and include response to stress and regulation of apoptosis. 
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These terms describe a generalized cellular response to stimulus and suggest that PBMCs isolated 
from IRIS patients may be subject to differentially regulated apoptotic pathways when exposed to re-
stimulation of the immune response, as GO terms relating to regulation of apoptosis were not 








Figure 83. Proteins identified in control and Mtb only samples from the IRIS group 
 
Table 25. Enriched GO terms for biological process in proteins common to both control and Mtb 
only samples from the IRIS group 
GO pathway ID Description Gene count False discovery rate 
GO:0065008 regulation of biological quality 124 1.27e-28 
GO:0006950 response to stress 123 8.29e-23 
GO:0010941 regulation of cell death 79 8.29e-23 
GO:0042981 regulation of apoptotic process 74 3.61e-21 
 
The 29 proteins unique to the control samples were analyzed using STRING, but did not form an 
enriched network and were therefore not investigated further. 
 
Finally, the 127 proteins unique to Mtb only samples produced a highly enriched STRING network, 
with enriched GO terms such as “symbiosis, encompassing mutualism through parasitism” 
(GO:0044403). In a previous analysis, this term was enriched in IRIS samples when comparing Mtb 
only samples from the non-IRIS and IRIS group. It is therefore a term that appears to be specific to the 
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IRIS samples after re-stimulation of the immune response. Notable proteins present in these samples 
are listed in Table 26. V-type proton ATPase subunit B (ATP6V1B2) and Ras-related protein Rab-7a 
(Rab7A) are both important in the maturation and acidification of the phagosome, as well as the fusion 
of the phagosome and lysosome. Rab7a appears to be particularly important in the context of Mtb 
infection, as Mtb is known to arrest phagosome/lysosome fusion at the stage at which Rab7 would 
normally be recruited. Seto et al.176 demonstrated that Rab7 is transiently recruited and removed from 
phagosomes containing Mtb. When Rab7 is released from this complex, recruitment of other factors 
such as cathepsin D and RILF is inhibited, thereby arresting phagolysosome fusion. It is therefore 
proposed that Mtb dysregulates the activity of certain Rab GTPases, thereby disrupting phagosome 
maturation, and enabling intracellular survival.  
 
Table 26. Key proteins unique to Mtb only samples from the IRIS group 
Protein ID Gene Protein name Role 
P21281 ATP6V1B2 V-type proton 
ATPase subunit B, 
brain isoform 
Phagosome acidification 
P51149 RAB7A Ras-related 
protein Rab-7a 
Phagosome maturation and acidification, 
phagosome/lysosome fusion 
 
We performed t-tests to compare protein expression between the Mtb-stimulated and control 
samples but no proteins were considered significantly differentially expressed after MTC. 
 
Mtb + vehicle vs Mtb + PUFA samples 
Non-IRIS group 
Next, we investigated the effects of pre-treating PBMCs with n-3 PUFA before re-stimulating with Mtb 
WCL by comparing protein expression from Mtb + vehicle and Mtb + PUFA samples using a Venn 
diagram (Figure 84). Of the 465 proteins quantified across Mtb + vehicle and Mtb + PUFA samples, 326 
(70.11%) were common to both conditions, 58 were unique to Mtb + vehicle samples, and 81 were 
unique to Mtb + PUFA samples. From this analysis, we expected to see a greater number of proteins 
associated with inflammation expressed in the Mtb + vehicle samples, and more proteins associated 











Figure 84. Proteins identified in Mtb + vehicle and Mtb + PUFA samples from the non-IRIS group 
 
Mtb + vehicle (non-IRIS group) 
To verify this hypothesis, we analyzed the 58 proteins quantified only in Mtb + vehicle samples using 
STRING. A network of 58 nodes and 78 edges was formed with several enriched GO terms, as listed in 
Table 13. The two enriched KEGG pathway terms relate to the inflammatory response to bacterial 
infection, and include several key pro-inflammatory mediators. In this dataset, we identified IL-6, 
ARPC3 and ARPC5, CDC42, and ASC. ASC, or apoptosis-associated speck-like protein containing a CARD 
(also referred to as PYCARD, Q9ULZ3), a key mediator of apoptosis and inflammation, is an adapter 
protein involved in the macromolecular formation of the NLRP3 inflammasome, along with pro-
caspase 1. Caspase 1 then drives the production of IL-1β and IL-18.177 The fact that ASC was only 
quantified in Mtb + vehicle samples and not Mtb + PUFA samples implies that its expression in Mtb-
stimulated PBMCs was lowered by PUFA pre-treatment. This observation is supported by the recent 
study by Sui et al. who demonstrated that DHA could inhibit NLRP3 inflammasome expression in 
hepatocytes by inhibiting NF-κB activity. Another study published similar results, reporting EPA and 
DHA’s ability to inhibit caspase 1 and IL-1β through inhibition of NLRP3 and interaction with GPR40 































Table 27. Enriched GO terms for biological process and KEGG pathway in proteins only quantifiable 
in Mtb + vehicle samples (non-IRIS group) 
GO pathway ID Description Gene 
count 
False discovery 
rate Biological process 
GO:0007264 small GTPase mediated signal transduction 10 0.0312 
GO:0019752 carboxylic acid metabolic process 11 0.0312 
GO:0042981 regulation of apoptotic process 14 0.0312 
KEGG pathway 
05132 Salmonella infection 5 0.000958 
05100 Bacterial invasion of epithelial cells 4 0.00785 
 
 
Mtb + PUFA (non-IRIS group) 
The 81 proteins identified only in Mtb + PUFA samples produced a STRING network with 81 nodes 





























Table 28. Enriched GO terms for biological process and KEGG pathway in proteins only quantifiable 
in Mtb + PUFA samples (non-IRIS group) 
GO pathway ID Description Gene 
count 
False discovery 
rate Biological process 
GO:0002474 antigen processing and presentation of peptide 
antigen via MHC class I 
6 0.00609 
GO:0016032 viral process 13 0.00609 
GO:0016071 mRNA metabolic process 12 0.00609 
GO:0051704 multi-organism process 23 0.00609 
KEGG pathway 
04145 Phagosome 7 0.000435 
03040 Spliceosome 6 0.000875 
04142 Lysosome 6 0.000875 
 
The most enriched term for biological process was “antigen processing and presentation of peptide 
antigen via MHC class I”. This was a surprising result, as the effects of n-3 PUFA supplementation on 
antigen presentation are well documented, and such fatty acids are understood to inhibit antigen 
presentation.179–181 It is unclear why the same effects are not observed here, but it must be noted that 
any observations made in the current experiment are those resulting from treatment with n-3 PUFA 
and stimulation with Mtb WCL. We were unable to find precedent in the literature for the combined 
effects of these two perturbation agents. 
 
T-tests performed did not reveal any significantly differentially expressed proteins when comparing 
the Mtb + vehicle and Mtb + PUFA samples from the non-IRIS group. 
 
IRIS group 
We repeated the comparison of Mtb + vehicle and Mtb + PUFA samples for the IRIS group. Of the 913 
proteins quantified, 456 (49.94%) were common to both conditions while 43 were unique to Mtb + 
vehicle samples, and 141 were unique to Mtb + PUFA samples (Figure 87). We noted that there were 
many more proteins quantified for these two conditions in the IRIS group than in the non-IRIS group 
(913 vs 465, respectively, Figure 84). This may suggest exacerbated responses from the IRIS patient-
derived cells. Similarly, there are more proteins unique to Mtb + PUFA samples in this group (141 vs 










Figure 87. Proteins identified in Mtb + vehicle and Mtb + PUFA samples from the IRIS group 
 
Mtb + vehicle (IRIS group) 
The 43 proteins unique to Mtb + vehicle samples in the IRIS group did not form an enriched network 
in the STRING protein interaction database. Several proteins in this dataset were also uniquely 
quantified in Mtb + vehicle samples from the non-IRIS group (such as ASC and IL-6). This is consistent 
with previous proteomic work by Bell et al.,166 which suggests that PBMCs derived from TB-IRIS 
patients showed an uncoordinated inflammatory response to the Mtb antigen stimulation. 
 
Mtb + PUFA (IRIS group) 
The 141 proteins uniquely identified here formed a STRING network comprising 139 nodes and 266 
edges (Figure 88). The enriched GO terms for biological process are listed in Table 29. Enriched GO 
terms for biological process in proteins only quantifiable in Mtb + PUFA samples (IRIS group). The term 
“component organization” may refer to the formation of lipid rafts, and interaction of n-3 PUFA with 
lipid rafts and other membrane components. This is also consistent with the reported proteomic 
effects of prednisone on Mtb-stimulated PBMCs from TB-IRIS patients, which showed increased 
cellular organization.166 Protein kinase C-α (PKCα, P17252) was identified here, and is an important 
kinase involved in the regulation of apoptosis, inflammation, and cell proliferation, differentiation, 
and migration. N-3 PUFA are known to modulate the effects of PKCα in various ways, such as inhibiting 
activation by blocking recruitment of PKCα,182 and modulating IL-2 gene expression by inducing 
















Table 29. Enriched GO terms for biological process in proteins only quantifiable in Mtb + PUFA 
samples (IRIS group) 
GO pathway ID Description Gene 
count 
False discovery 
rate Biological process 
GO:0044281 small molecule metabolic process 38 1.97e-05 
GO:0048193 Golgi vesicle transport 11 0.00225 
GO:0051128 regulation of cellular component organization 33 0.00225 
GO:0051704 multi-organism process 23 0.00609 
 
We performed t-tests and identified 20 proteins that are considered significantly differentially 
expressed (permutation-based FDR MTC applied), 15 of which were down-regulated in Mtb + PUFA 
samples (Table 30) and five were up-regulated (Table 31). CDC42 is associated with Fc-γ receptor-
mediated phagocytosis, which has previously been implicated in TB-IRIS.166 Previous proteomic 
analysis of Mtb-simulated PBMCs from non-IRIS and IRIS patients highlighted a deficit in Fc-γ receptor-
mediated phagocytosis in PBMCs from IRIS patients, implying a defect in antigen clearance in these 
patients. Our findings, which suggest n-3 PUFA mediates up-regulation of Fc-γ receptor-mediated 
phagocytosis components, may therefore be significant, as this is  a normal response to Mtb antigens 
in active TB patients.  
 
Two of the five down-regulated proteins are associated with the integrin pathway, which mediates 
responses at the cell surface such as signal transduction, cell migration, and cell adhesion. Several 
down-regulated proteins are associated with the immune response (PSMB2, A1AT, AGA, CD11, CD18, 
HLA-DRB1, CLTC, and CPN1), particularly neutrophil degranulation, antigen presentation, cell 
migration, and signalling pathways. Since these proteins are down-regulated in Mtb + PUFA samples, 
this suggests that pre-treatment with n-3 PUFA may be causing the observed effect in PBMCs re-
stimulated with Mtb WCL. This may therefore support the beneficial role of n-3 PUFA treatment in 




Table 30. Down-regulated proteins in Mtb + PUFA samples from the IRIS group  
Protein ID Gene Protein name Function* P-value Fold-
change** 
q value 
P04179 SOD2 Superoxide dismutase [Mn], 
mitochondrial 
Removal of superoxide radicals, oxidative 
stress, IL-12 signaling pathways 
4.49e-03 -3.62 0.0444 
Q04837 SSBP1 Single-stranded DNA-binding 
protein, mitochondrial 
DNA replication, mitochondrial organization 3.04e-03 -3.39 0.0633 
 
P00505 GOT2 Aspartate aminotransferase, 
mitochondrial 
Amino acid metabolism, cellular uptake of 
long-chain fatty acids 
1.52e-03 -3.20 0.0568 
P49721 PSMB2 Proteasome subunit beta type-
2 (PSMB2) 
NIK/NF-κB, TNF-α, and T cell receptor 
signaling pathways 
4.50e-03 -2.97 0.0422 
P01009 SERPINA1 Alpha-1-antitrypsin (A1AT) Acute phase response, coagulation, 
neutrophil/platelet degranulation 
2.16e-03 -2.62 0.0607 
 





Peptidase, neutrophil degranulation 4.43e-03 -2.55 0.4689 
Q13011 ECH1 Delta(3,5)-Delta(2,4)-dienoyl-
CoA isomerase, mitochondrial 
Fatty acid beta oxidation 3.03e-03 -2.37 0.0691 
 
P05107 ITGB2 Integrin beta-2 (CD18) Inflammatory response, leukocyte 
recruitment and adhesion, dimer with CD11 
2.78e-03 -2.33 0.0711 
 
P20073 ANXA7 Annexin A7 Autophagy, cell proliferation, calcium/water 
homeostasis 
4.25e-03 -2.09 0.4965 
153 
 
P62310 LSM3 U6 snRNA-associated Sm-like 
protein LSm3 
mRNA processing and splicing 4.15e-03 -1.94 0.0563 
 
P20701 ITGAL Integrin alpha-L 
(CD11) 
Inflammatory response, leukocyte migration, 
phagocytosis, dimer with CD18 
9.29e-04 -1.73 0.0200 
Q07493 HLA-
DRB1 
HLA class II histocompatibility 
antigen, DRB1-15 beta chain 
Antigen processing and presentation via MHC 
class II, IFN-γ-mediated signaling, T cell 
stimulation and signaling 
4.23e-03 -1.64 0.0528 
Q00610 CLTC Clathrin heavy chain 1 Antigen processing and presentation via MHC 
class II, plasma membrane organization, 
autophagy  
2.99e-03 -1.29 0.0640 
 
P07384 CAPN1 Calpain-1 catalytic subunit Neutrophil degranulation, cell proliferation, 
macroautophagy 
5.38e-04 -1.06 0.0400 
*From UniProt (www.uniprot.org) 













Table 31. Up-regulated proteins in Mtb + PUFA samples from the IRIS group  
Protein ID Gene Protein name Function* P-value Fold-
change** 
q value 
P60953 CDC42 Cell division control 
protein 42 homolog 
Fc-γ receptor-mediated phagocytosis, integrin 
pathway 
3.36e-03 +1.32 0.0543 
P49321 NASP Nuclear autoantigenic 
sperm protein 
Cell proliferation, DNA replication 2.59e-03 +1.49 0.0914 
 
O75995 SASH3 SAM and SH3 domain-
containing protein 3 
B and T cell proliferation, production of IFN-γ, IL-10, 
IL-2, and IL-4  
2.64e-03 +1.87 0.08 
P08567 PLEK Plekstrin Integrin pathway, platelet activation/degranulation 1.94e-04 +2.14 0 
P31946 YWHAB 14-3-3 protein 
beta/alpha 
MAPK cascade, membrane organization 8.94e-04 +2.57 0.0267 
*From UniProt (www.uniprot.org) 





In this experiment, we aimed to i) identify differences in the secretome of PBMCs from non-IRIS and 
IRIS patients treated under various conditions, and ii) investigate the effects of re-stimulation with 
Mtb WCL and pre-treatment with n-3 PUFA on PBMCs derived from non-IRIS and IRIS patients. 
Although most of the analyses performed were qualitative based on presence/absence analyses 
rather than differential expression analyses, we were able to deduce some conclusions.  
 
In control samples (PBMCs cultured ex vivo without external stimulus), cells from the non-IRIS and IRIS 
group produced different results. IRIS group cells secreted a greater number of proteins than their 
non-IRIS counterparts, and both groups clustered separately when protein expression was subjected 
to PCA. This was in line with previous reports in the literature of differing inflammatory marker levels 
both at baseline (ART initiation) and after two weeks. In Mtb only samples, key inflammatory 
mediators were identified only in the IRIS group samples, suggesting a greater inflammatory response 
in this group. However, there were no significantly differentially expressed proteins identified 
between non-IRIS and IRIS group samples, across all treatment conditions, and PCA did not reveal 
clustering in any of the treatment conditions other than controls.  
 
When we compared control and Mtb only samples within each patient group, we found that PBMCs 
re-stimulated with Mtb WCL secreted more proteins than their unstimulated counterparts. This 
observation was true in both the non-IRIS and IRIS groups, although the difference in protein groups 
quantified was much smaller in IRIS group samples, suggesting that the inflammatory response 
induced by re-stimulation was already present at baseline. This is to be expected as TB-IRIS is 
characterized by aberrant inflammatory responses. 
 
When comparing Mtb + PUFA and Mtb + vehicle samples, we observed that several pro-inflammatory 
proteins were quantifiable only in Mtb + vehicle samples and not Mtb + PUFA samples, suggesting that 
pre-treatment of Mtb-stimulated PBMCs with n-3 PUFA may have caused down-regulation of these 
inflammatory mediators. Although t-tests performed on non-IRIS group samples did not reveal any 
significantly up-/down-regulated proteins, we identified 20 differentially expressed proteins in the IRIS 
group samples. Several proteins down-regulated in Mtb + PUFA samples were associated with 
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pathways relating to inflammation and the immune response, further supporting the hypothesis that 
n-3 PUFA may lead to the resolution of TB-IRIS-associated inflammation. 
 
This experiment holds several limitations. The sample size was small, and inherent biological variation 
or “noise” is therefore much more prominent. The fact that we did not include a PUFA only control 
also partly hampers our ability to tease out which effects observed arise from n-3 PUFA treatment and 
which may be due to re-stimulation with Mtb WCL. Finally, we must make the assumption that the 
presence/absence of proteins observed is an accurate reflection of the cells’ biological state in the 
various samples, and not sampling error. Although some of these limitations are inherent to label-free 









9.1 Summary of findings 
As outlined in Chapter 2, the current study aimed to (i) investigate the effects of re-stimulating healthy 
donor and IRIS/non-IRIS patient-derived PBMCs with Mtb WCL, (ii) investigate the effects of n-3 PUFA 
pre-treatment on Mtb WCL-stimulated healthy donor and patient-derived PBMCs, and (iii) identify any 
differences in the responses of non-IRIS and IRIS patients-derived PBMCs to Mtb WCL stimulation and 
n-3 PUFA treatment. These research aims were fulfilled through the use of label-free, MS-based 
proteomic methods. Although this study could not provide complete answers for these three 
statements, we were able to shed some light on the effects of n-3 PUFA in the context of TB-IRIS, as 
summarized here. 
 
In Chapter 4, we aimed to optimise the cell culture platform and ensure that cell isolation, 
preservation, and culture conditions were appropriate for cell survival. We showed that PBMCs 
isolated from healthy donors could be cultured for 48 h with Mtb WCL, with and without the addition 
of n-3 PUFA or the vehicle, with no significant decrease in cell survival. We also tested cell survival in 
the presence of n-3 PUFA at three different concentrations, including twice the concentration used 
later on in the study, in order to confirm that n-3 PUFA treatment was not harmful to PBMCs. This 
preliminary work enabled us to test the effects of re-stimulation with Mtb WCL and pre-treatment 
with n-3 PUFA in an in vitro cell model that is partly representative of TB-IRIS. 
 
The following chapter (Chapter 5) describes an experiment that was designed to test the sample 
processing methods, and to evaluate technical and biological variation, as well as reproducibility. 
Through this experiment, we confirmed that we had isolated the PBMC secretome, and optimized the 
sample processing methods. Correlation between the technical replicates was satisfactory, and the 
PCA showed that samples could be differentiated based on their protein expression profile in response 
to Mtb WCL re-stimulation.  
 
Next, we investigated the changes associated with the re-stimulation of PBMCs with Mtb WCL, and 
pre-treatment with n-3 PUFA (Chapter 6). We identified over 2000 protein groups, 727 of which were 
secreted human proteins, including three interleukins. Contrary to studies reported in the literature, 
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we did not observe significant dysregulation of protein expression in PBMCs re-stimulated with Mtb 
WCL. However, we identified possible reasons for this (discussed in Chapter 6), which include low TIC 
in Mtb only samples compared to control samples. We also identified several proteins from the 
complement and coagulation pathways quantified in Mtb + vehicle samples but not quantifiable in 
Mtb + PUFA samples. This may suggest down-regulation of these pathways by n-3 PUFA in Mtb WCL-
stimulated PBMCs, and supports the hypothesis that n-3 PUFA may be exerting an anti-inflammatory 
effect in this context. 
 
In Chapters 7 and 8, we repeated the previous experiment using PBMCs derived from TB- and HIV-
infected patients who developed TB-IRIS, compared with those from patients co-infected with TB and 
HIV but who did not go on to develop TB-IRIS. We first compared the secretome of PBMCs from non-
IRIS and IRIS patients treated under various conditions and observed that protein expression differed 
between these two groups. IRIS group cells secreted a greater number of proteins than cells from the 
non-IRIS group, and expressed more inflammatory mediators (such as IL-1β, identified in control 
samples). In Mtb WCL-stimulated samples, key proteins associated with inflammation were identified 
uniquely in IRIS group samples (such as IL-6 and IL-16, identified in Mtb-stimulated samples), 
suggesting a greater inflammatory response in this group. 
 
Finally, we investigated the effects of re-stimulation with Mtb WCL and pre-treatment with n-3 PUFA 
on PBMCs derived from non-IRIS and IRIS patients. Re-stimulation with Mtb WCL induced increased 
protein expression in both the non-IRIS and IRIS group, several pathways relating to the immune 
response and bacterial invasion were up-regulated in these samples, and inflammatory mediators IL-
1α and IL-1β were identified. We did not find any significantly dysregulated proteins when comparing 
n-3 PUFA-treated cells with their vehicle-treated counterparts from the non-IRIS group. However, 
when the same comparison was made with IRIS group samples, we observed that n-3 PUFA-treated 
cells secreted many more proteins, and we identified 20 proteins that were significantly dysregulated 
in this treatment group. Several of these were associated with the integrin pathway, which mediates 
responses at the cell surface such as signal transduction, cell migration, and cell adhesion, and one 
protein associated with Fc-γ-mediated phagocytosis (CDC42). Encouragingly, eight of the 15 down-
regulated proteins were associated with inflammation and the immune response (PSMB2, A1AT, AGA, 
CD11, CD18, HLA-DRB1, CLTC, and CPN1). This further supports the hypothesis that n-3 PUFA may 
potentially lead to the resolution of TB-IRIS-associated inflammation. 
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The data obtained showed that PBMCs re-stimulated with Mtb WCL mount an immune response, that 
is at least partly mitigated by pre-treatment with n-3 PUFA. This was true for healthy donor samples, 
as well as non-IRIS and IRIS patient-derived samples. However, since most of the analyses performed 
were qualitative, based on presence/absence analyses, rather than quantitative, the data would need 
to be confirmed by targeted MS analysis in a larger cohort. The current study therefore provides 
positive reinforcement for the theory that n-3 PUFA may hold benefits for patients suffering from TB-
IRIS-associated inflammatory symptoms.   
 
9.2 Discussion of problems and limitations 
The main flaws and limitations in the current work should be acknowledged here to inform future 
work.  
Sample size 
As mentioned in the text, the number of samples investigated in the present study is limited (healthy 
volunteers, n = 8; patients, n = 10). With a small sample group, biological variability may mask 
treatment-specific trends in the data, and prevent from drawing definite conclusions. This would easily 
be improved by increasing the sample size. The appropriate sample size could be calculated using a 
power equation to ensure results obtained are significant. 
 
TIC variation and MS data quality 
Some of the experiments performed here yielded lower quality MS data than would be desired, and 
would have warranted repeat submissions. However, due to constraints relating to time and machine 
use and sample availability, this was not always possible. This may have affected our ability to perform 
quantitative analyses, as seen in Chapter 6. 
 
PUFA-only control 
The four treatment conditions tested included an untreated and unstimulated control, as well as a 
vehicle control. However, inclusion of a PUFA-only control would have been useful to compare the 
effect of n-3 PUFA in Mtb-stimulated cells with that in cells not stimulated with Mtb WCL. This would 
have allowed us to tease out the effects of both these perturbations, rather than observation of the 




Complex nature of TB-IRIS 
In the current study, we have tested n-3 PUFA in what may be referred to as an in vitro model of TB-
IRIS. “All models are wrong, but some are useful”, as the statistician George Box once said, and in our 
case this is particularly pertinent. TB-IRIS is a complex, system-wide disorder that includes several 
factors not accounted for in the present work. These include the presence of live Mtb and HIV, anti-
TB and ART drugs (and possibly prednisone), and interaction with different cells types not present in 
this sample (other PBMCs which would have depleted here, particularly adherent monocytes and 
macrophages, and other blood components). Clinical work would therefore provide a much holistic 
view of the TB-IRIS system and its response to n-3 PUFA treatment.  
 
Interaction with prednisone 
Finally, as prednisone is currently the drug used to relieve TB-IRIS-associated symptoms, the 
interaction of n-3 PUFA with prednisone (and other anti-TB and ART drugs) would be particularly 
relevant, and has not been addressed in the current work.  
 
9.3 Summary of contributions 
The current work provides preliminary in vitro data for the use of n-3 PUFA in TB-IRIS patients. The 
use of n-3 PUFA in treating patient-derived PBMCs may be related to dietary supplementation in vivo 
and included in a clinical trial. Since the safety of dietary n-3 PUFA consumption has been researched 
extensively and proven, there is no danger to the patient, and our work has shown its potential 
benefits in the relief of TB-IRIS-associated symptoms. 
 
9.4 Suggestions for further research 
Prednisone is a corticosteroid currently used in the treatment of TB-IRIS. It has broad anti-
inflammatory activity. Since n-3 PUFA and prednisone exert anti-inflammatory effects through 
different mechanisms, there may be possible synergism when both are used concurrently. This has 
important implications for TB-IRIS, as patients being treated with prednisone could gain extra benefits 
from dietary supplementation with n-3 PUFA. This is an area which should be investigated further in 
the future, at the in vitro level initially. Briefly, the same experiment described here could be repeated 
with the addition of prednisone (in the form of prednisolone, or dexamethasone as in the work 
performed by Bell et al.166) to the cell culture. Additionally, further experiments using PBMC samples 
from patients with IRIS under prednisone treatment could be performed to assess the responses of 
IRIS patient-derived, prednisone-exposed PBMCs to re-stimulation with Mtb and treatment with n-3 
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PUFA. This may shed light on the modulation of the immune response by prednisone and n-3 PUFA in 
the context of TB-IRIS.  
 
In terms of the next step in this work, targeted proteomic work involving a larger cohort may be 
needed to verify and validate the results from this preliminary study. If this follow-up study confirms 
our results, clinical work may be warranted. The preliminary in vitro data shown here suggests that 
clinical use of n-3 PUFA in patients with TB-IRIS may relieve inflammation. A clinical trial that includes 
dietary supplementation with n-3 PUFA would be needed to confirm this hypothesis in vivo. N-3 PUFA 
are safe immuno-modulatory agents, have been used successfully in the treatment of other 
inflammatory diseases, and can easily be obtained from the diet. They carry the added advantage of 
cost-efficiency as can be found in affordable products such as tinned sardines. This is particularly 
relevant in the South African context and would help reduce the number of medications administered 
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Appendix A: Preparation and Contents of Reagents 
 Note: In the following appendix, 'water' refers to high-purity HPLC-MS-grade water. 
 
Preparation of glassware 
All glassware used in the preparation of reagents used in proteomics experiments were prepared in 
order to remove any contaminants and detergents remaining inside the glassware after normal 
cleaning.  Glassware was washed once with water, followed by three washes with MS-grade methanol, 
and a final wash with water. The glassware was then left to air-dry upside down on absorbent paper. 
 
Reagent recipes 
0.05M ammonium bicarbonate (ABC) 
0.0197 g ABC (Sigma, 09830) was dissolved in 5 mL water. 
 
Denaturation buffer 
In 40 mL 10 mM Tris-Cl pH 8 was dissolved 14.41 g urea and 6.088 g thiourea. The solution was mixed 
by inversion on a rotator for 1 h until dissolved. The denaturation buffer was stored at -20 °C in 2 mL 
aliquots and used within 3 months. 
 
5% DOC stock 
2.5 g DOC (Sigma, D6750) was dissolved in 25 mL water, and topped up to 50 mL, before shaking on 
vortex for 5 min. The solution was then mixed by inversion on a rotator for 30 min before transferring 
to an amber vial for long-term storage at 4 °C. 
 
5X dithiothreitol (DTT) stock for FASP 
0.185 g DTT was dissolved in 1.2 mL water. 
 
1.5M HEPES buffer 
17.8725 g HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-hydroxyethyl)piperazine-
N′-(2-ethanesulfonic acid ), Sigma, H3375) was dissolved in 30 mL MS-grade water. The pH was 
adjusted to 7.4 using 1 M NaOH, made up by dissolving 2 g NaOH (Merck Millipore, 106462) in 50 mL 
water and filtered through a 0.2 um filter. After pH adjustment, the HEPES solution was topped up to 




0.5 M iodoacetamide (IAA) for FASP 
0.0185 g IAA (Amresco, M216) was dissolved in 2 mL UA, vortexed and covered with foil. 
 
0.55 M IAA alkylation buffer 
0.1017 g IAA was dissolved in 1 mL 0.02 M ABC. 
 
3X RIPA lysis buffer 
3X RIPA buffer was prepared by combining 5 mL 1.5 M HEPES buffer, 15 mL 5% DOC, and 15 mL 20% 
SDS. The solution was warmed to 40 °C on a heating plate and 1.3 g sodium chloride (NaCL, Sigma, 
S7653) was slowly added. The solution was transferred to amber vials in 7 mL aliquots was stored at 
room temperature. Just before use, 3 protease inhibitor tablets (cOmplete™ ULTRA Tablets, Mini, 
EDTA-free, EASYpackProtease Inhibitor Cocktail, Roche, 05892791001) were dissolved in 3 mL water 
and added to 7 mL of the 3X RIPA buffer. 
 
20% sodium dodecyl sulphate (SDS) stock 
20 g SDS (Sigma, L4390) was dissolved in 100 mL water warmed to 60 °C and mixed by magnetic stirring 
at low speed for 30 min. The solution was then stored at room temperature. 
 
Trypsin 
Trypsin-Ultra (MS-grade, New England Biolabs (NEB), P8101S) was reconstituted by adding 20 µL 
water per vial and triturating gently several times. 
 
Trypsin-Ultra Reaction buffer 
2X Trypsin-Ultra Reaction buffer (NEB), containing 50 mM Tris-CL, 20 mM CaCl2 at pH8 was used in 
conjunction with Trypsin-Ultra (NEB, P8101S) according to the manufacturer's instructions. 
 
1 M Tris-Cl, pH 8.5 
30.29 g Trizma base (Sigma, T6066) was dissolved in 200 mL water and pH was adjusted to 8.5 using 
37% hydrochloric acid (HCl, Sigma, 258148). The solution was topped up to 250 mL with water. 
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0.1 M Tris-Cl, pH 8.5 
3 mL 1 M Tris-Cl, pH 8.5 was added to 27 mL of water and inverted to ensure mixing. 
 
8 M urea buffer (UA) 
9.6 g urea (Sigma, 33247) was added to 20 mL 0.1M Tris-Cl pH 8.5 and inverted several times to 
dissolve. 
 
